<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2607222351
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VIMPAT 10 mg/ml SYRUP
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LACOSAMIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Syrup
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        96.80
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Unither Manufacturing LLC " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Unither Manufacturing LLC 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            U.C.B.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N03AX18
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Vimpat is and what it is used for</strong></p><p>&nbsp;</p><p><strong>What Vimpat is</strong></p><p>Vimpat contains lacosamide. This belongs to a group of medicines called &ldquo;antiepileptic medicines&rdquo;. These medicines are used to treat epilepsy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have been given this medicine to lower the number of fits (seizures) you have.</p><p>&nbsp;</p><p><strong>What Vimpat is used for</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vimpat is used in adults, adolescents and children aged 4&nbsp;years and older.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is used to treat a certain type of epilepsy characterised by the occurrence of partial-onset seizure with or without secondary generalisation.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In this type of epilepsy, fits first affect only one side of your brain. However, these may then spread to larger areas on both sides of your brain.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vimpat may be used on its own or with other antiepileptic medicines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you need to know before you take Vimpat </strong></p><p>&nbsp;</p><p><strong>Do not take Vimpat</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to lacosamide, or any of the other ingredients of this medicine (listed in Section&nbsp;6). If you are not sure whether you are allergic, please discuss with your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a certain type of heart beat problem called second- or third-degree AV block.</p><p>&nbsp;</p><p>Do not take Vimpat if any of the above applies to you. If you are not sure, talk to your doctor or pharmacist before taking this medicine.</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor before taking Vimpat if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have thoughts of harming or killing yourself. A small number of people being treated with antiepileptic medicinal products such as lacosamide have had thoughts of harming or killing themselves. If you have any of these thoughts at any time, tell your doctor straight away.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have a heart problem that affects the beat of your heart and you often have a particulary slow, fast or irregular heart beat (such as AV block, atrial fibrillation or atrial flutter).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have severe heart disease such as heart failure or have had a heart attack.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are often dizzy or fall over.<strong> </strong>Vimpat may make you dizzy &ndash; this could increase the risk of accidental injury or a fall. This means that you should take care until you are used to the effects of this medicine.</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking Vimpat.</p><p>If you are taking Vimpat and you are experiencing symptoms of abnormal heartbeat (such as slow, rapid or irregular heartbeat, palpitations, shortness of breath, feeling lightheaded, fainting), seek medical advice immediately (see section 4).</p><p>&nbsp;</p><p><strong>Children under 4&nbsp;years</strong></p><p>Vimpat is not recommended for children aged under 4&nbsp;years. This is because we do not yet know whether it will work and whether it is safe for children in this age group.</p><p>&nbsp;</p><p><strong>Other medicines and Vimpat</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>In particular, tell your doctor or pharmacist if you are taking any of the following medicines that affect your heart - this is because Vimpat can also affect your heart:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to treat heart problems;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines which can increase the &ldquo;PR interval&rdquo; on a scan of the heart (ECG or electrocardiogram) such as medicines for epilepsy or pain called carbamazepine, lamotrigine or pregabalin;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat certain types of irregular heart beat or heart failure.</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking Vimpat.</p><p>&nbsp;</p><p>Also tell your doctor or pharmacist if you are taking any of the following medicines - this is because they may increase or decrease the effect of Vimpat on your body:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for fungal infections called fluconazole, itraconazole or ketoconazole;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a medicine for HIV called ritonavir;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for bacterial infections called clarithromycin or rifampicin;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a herbal medicine used to treat mild anxiety and depression called St.&nbsp;John&rsquo;s wort.</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking Vimpat.</p><p>&nbsp;</p><p><strong>Vimpat with alcohol</strong></p><p>As a safety precaution do not take Vimpat with alcohol.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>It is not recommended to take Vimpat if you are pregnant or breast-feeding, as the effects of Vimpat on pregnancy and the unborn baby or the new-born child are not known. Also, it is not known whether Vimpat passes into the breast milk. Seek advice immediately from your doctor if you get pregnant or are planning to become pregnant. They will help you decide if you should take Vimpat or not.</p><p>&nbsp;</p><p>Do not stop treatment without talking to your doctor first as this could increase your fits (seizures). A worsening of your disease can also harm your baby.</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong></p><p>Do not drive, cycle or use any tools or machines until you know how this medicine affects you. This is because Vimpat may make you feel dizzy or cause blurred vision.</p><p><strong>&nbsp;</strong></p><p><strong>Vimpat contains sorbitol, sodium, sodium methyl parahydroxybenzoate and aspartame</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sorbitol (a type of sugar): If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sodium (salt):</p><p>o&nbsp;&nbsp; there are 7.09&nbsp;mg sodium in each graduation mark (5&nbsp;ml) of the measuring cup. If you take more than 3 graduation marks of syrup each day and are on a controlled sodium diet, take this into consideration.</p><p>o&nbsp;&nbsp; there are 3.5 mg sodium in each 2.5 ml dose from the oral syringe. If you take more than 12.5 ml of syrup each day and are on a controlled sodium diet, take this into consideration.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sodium methyl parahydroxybenzoate (E219) may cause allergic reactions (possibly delayed).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Aspartame (E951): a source of phenylalanine. This substance may be harmful for people with phenylketonuria (a rare metabolic disease).</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to take Vimpat </strong></p><p><u>&nbsp;</u></p><p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>Taking Vimpat</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take Vimpat twice each day - once in the morning and once in the evening.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Try to take it at about the same time each day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may take Vimpat with or without food.</p><p>&nbsp;</p><p>You will usually start by taking a low dose each day and your doctor will slowly increase this over a number of weeks. When you reach the dose that works for you, this is called the &ldquo;maintenance dose&rdquo;, you then take the same amount each day. Vimpat is used as a long term treatment. You should continue to take Vimpat until your doctor tells you to stop.</p><p>&nbsp;</p><p><strong>How much to take</strong></p><p>Listed below are the normal recommended doses of Vimpat for different age groups and weights. Your doctor may prescribe a different dose if you have problems with your kidneys or with your liver.</p><p>&nbsp;</p><p><strong>Adolescents</strong><strong> and children weighing 50</strong>&nbsp;<strong>kg or more </strong><strong>and adults</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use the measuring cup provided in the carton box.</p><p><u>&nbsp;</u></p><p><u>When you take Vimpat on its own</u></p><p>The usual starting dose of Vimpat is 50&nbsp;mg (5&nbsp;ml) twice a day.</p><p>Your doctor may also prescribe a starting dose of 100&nbsp;mg (10&nbsp;ml) of Vimpat twice a day.</p><p>&nbsp;</p><p>Your doctor may increase your twice daily dose every week by 50&nbsp;mg (5&nbsp;ml). This will be until you reach a maintenance dose of between 100&nbsp;mg (10&nbsp;ml) and 300&nbsp;mg (30&nbsp;ml) twice a day.</p><p><u>&nbsp;</u></p><p><u>When you take Vimpat with other antiepileptic medicines</u></p><p>The usual starting dose of Vimpat is 50&nbsp;mg (5&nbsp;ml) twice a day.</p><p>&nbsp;</p><p>Your doctor may increase your twice daily dose every week by 50&nbsp;mg (5&nbsp;ml). This will be until you reach a maintenance dose of between 100&nbsp;mg (10&nbsp;ml) and 200&nbsp;mg (20&nbsp;ml) twice a day.</p><p>&nbsp;</p><p>If you weigh 50&nbsp;kg or more, your doctor may decide to start Vimpat treatment with a single &ldquo;loading&rdquo; dose of 200&nbsp;mg (20&nbsp;ml). You would then start your ongoing maintenance dose 12&nbsp;hours later.</p><p>&nbsp;</p><p><strong>Children and adolescents weighing less than 50</strong>&nbsp;<strong>kg</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use the oral syringe provided in the carton box.</p><p>&nbsp;</p><p><u>When you take Vimpat on its own</u></p><p>&nbsp;</p><p>Your doctor will decide the dose of Vimpat based on your body weight.</p><p>&nbsp;</p><p>The usual starting dose is 1&nbsp;mg (0.1&nbsp;ml), for each kilogram (kg) of body weight, twice a day.</p><p>&nbsp;</p><p>Your doctor may then increase your twice daily dose every week by 1&nbsp;mg (0.1&nbsp;ml), for each kg of your body weight. This will be until you reach a maintenance dose. The maximum recommended dose is 6&nbsp;mg (0.6&nbsp;ml) for each kg of body weight, twice a day, for children weighing under 40&nbsp;kg. The maximum recommended dose is 5&nbsp;mg (0.5&nbsp;ml) for each kg of body weight, twice a day, for children weighing from 40 kg to under 50 kg. Dosing charts are provided below:</p><p>&nbsp;</p><p>Taking Vimpat on its own &ndash; This is for information only. Your doctor will work out the right dose for you:<strong> </strong></p><p>&nbsp;</p><p><strong>To be taken twice daily</strong> for children from 4&nbsp;years of age <strong>weighing less than 40&nbsp;kg</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Weight</p></td><td style="vertical-align:top"><p>Starting dose: 0.1 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.2 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.3 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.4 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.5 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Maximum recommended dose: 0.6 ml/kg</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>10 kg</p></td><td style="vertical-align:top"><p>1 ml</p></td><td style="vertical-align:top"><p>2 ml</p></td><td style="vertical-align:top"><p>3 ml</p></td><td style="vertical-align:top"><p>4 ml</p></td><td style="vertical-align:top"><p>5 ml</p></td><td style="vertical-align:top"><p>6 ml</p></td></tr><tr><td style="vertical-align:top"><p>15 kg</p></td><td style="vertical-align:top"><p>1.5 ml</p></td><td style="vertical-align:top"><p>3 ml</p></td><td style="vertical-align:top"><p>4.5 ml</p></td><td style="vertical-align:top"><p>6 ml</p></td><td style="vertical-align:top"><p>7.5 ml</p></td><td style="vertical-align:top"><p>9 ml</p></td></tr><tr><td style="vertical-align:top"><p>20 kg</p></td><td style="vertical-align:top"><p>2 ml</p></td><td style="vertical-align:top"><p>4 ml</p></td><td style="vertical-align:top"><p>6 ml</p></td><td style="vertical-align:top"><p>8 ml</p></td><td style="vertical-align:top"><p>10 ml</p></td><td style="vertical-align:top"><p>12 ml</p></td></tr><tr><td style="vertical-align:top"><p>25 kg</p></td><td style="vertical-align:top"><p>2.5 ml</p></td><td style="vertical-align:top"><p>5 ml</p></td><td style="vertical-align:top"><p>7.5 ml</p></td><td style="vertical-align:top"><p>10 ml</p></td><td style="vertical-align:top"><p>12.5 ml</p></td><td style="vertical-align:top"><p>15 ml</p></td></tr><tr><td style="vertical-align:top"><p>30 kg</p></td><td style="vertical-align:top"><p>3 ml</p></td><td style="vertical-align:top"><p>6 ml</p></td><td style="vertical-align:top"><p>9 ml</p></td><td style="vertical-align:top"><p>12 ml</p></td><td style="vertical-align:top"><p>15 ml</p></td><td style="vertical-align:top"><p>18 ml</p></td></tr><tr><td style="vertical-align:top"><p>35 kg</p></td><td style="vertical-align:top"><p>3.5 ml</p></td><td style="vertical-align:top"><p>7 ml</p></td><td style="vertical-align:top"><p>10.5 ml</p></td><td style="vertical-align:top"><p>14 ml</p></td><td style="vertical-align:top"><p>17.5 ml</p></td><td style="vertical-align:top"><p>21 ml</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>To be taken twice daily</strong> for children and adolescents from 4&nbsp;years of age <strong>weighing 40</strong>&nbsp;<strong>kg to under 50&nbsp;kg</strong>:</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Weight</p></td><td style="vertical-align:top"><p>Starting dose: 0.1 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.2 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.3 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.4 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Maximum recommended dose: 0.5 ml/kg</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>40 kg</p></td><td style="vertical-align:top"><p>4 ml</p></td><td style="vertical-align:top"><p>8 ml</p></td><td style="vertical-align:top"><p>12 ml</p></td><td style="vertical-align:top"><p>16 ml</p></td><td style="vertical-align:top"><p>20 ml</p></td></tr><tr><td style="vertical-align:top"><p>45 kg</p></td><td style="vertical-align:top"><p>4.5 ml</p></td><td style="vertical-align:top"><p>9 ml</p></td><td style="vertical-align:top"><p>13.5 ml</p></td><td style="vertical-align:top"><p>18 ml</p></td><td style="vertical-align:top"><p>22.5 ml</p></td></tr></tbody></table><p>&nbsp;</p><p><u>When you take Vimpat with other antiepileptic medicines</u></p><p>&nbsp;</p><p>Your doctor will decide the dose of Vimpat based on your body weight.</p><p>&nbsp;</p><p>In children from 4&nbsp;years of age with a body weight of under 20&nbsp;kg:</p><ul><li>the usual starting dose is 1&nbsp;mg (0.1&nbsp;ml), for each kilogram (kg) of body weight, twice a day.</li></ul><p>&nbsp;</p><p>Your doctor may then increase your twice daily dose every week by 1&nbsp;mg (0.1&nbsp;ml) for each kg of body weight. This will be until you reach a maintenance dose. The maximum recommended dose is 6&nbsp;mg (0.6&nbsp;ml), for each kg of body weight, twice a day. A dosing chart is provided below.</p><p>&nbsp;</p><p>Taking Vimpat with other antiepileptic medicines - <strong>Children above 4 years of age weighing less than 20</strong>&nbsp;<strong>kg - </strong>This is for information only. Your doctor will work out the right dose for you:</p><p><strong>&nbsp;</strong></p><p><strong>To be taken twice daily</strong> for children from 4&nbsp;years of age <strong>weighing less than 20&nbsp;kg</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Weight</p></td><td style="vertical-align:top"><p>Starting dose: 0.1 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.2 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.3 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.4 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.5 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Maximum recommended dose: 0.6 ml/kg</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>10 kg</p></td><td style="vertical-align:top"><p>1 ml</p></td><td style="vertical-align:top"><p>2 ml</p></td><td style="vertical-align:top"><p>3 ml</p></td><td style="vertical-align:top"><p>4 ml</p></td><td style="vertical-align:top"><p>5 ml</p></td><td style="vertical-align:top"><p>6 ml</p></td></tr><tr><td style="vertical-align:top"><p>15 kg</p></td><td style="vertical-align:top"><p>1.5 ml</p></td><td style="vertical-align:top"><p>3 ml</p></td><td style="vertical-align:top"><p>4.5 ml</p></td><td style="vertical-align:top"><p>6 ml</p></td><td style="vertical-align:top"><p>7.5 ml</p></td><td style="vertical-align:top"><p>9 ml</p></td></tr></tbody></table><p>&nbsp;</p><p>In children from 4&nbsp;years of age with a body weight of 20 to under 30&nbsp;kg:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the usual starting dose is 1&nbsp;mg (0.1&nbsp;ml), for each kilogram (kg) of body weight, twice a day.</p><p>&nbsp;</p><p>Your doctor may then increase your twice daily dose every week by 1&nbsp;mg (0.1&nbsp;ml) for each kg of body weight. This will be until you reach a maintenance dose. The maximum recommended dose is 5&nbsp;mg (0.5&nbsp;ml), for each kg of body weight, twice a day. A dosing chart is provided below.</p><p>&nbsp;</p><p>Taking Vimpat with other antiepileptic medicines - <strong>Children and adolescents with a body weight of 20&nbsp;kg to under 30&nbsp;kg - </strong>This is for information only. Your doctor will work out the right dose for you:</p><p>&nbsp;</p><p><strong>To be taken twice daily</strong> for children and adolescents from 4 years of age <strong>weighing 20</strong>&nbsp;<strong>kg to under 30&nbsp;kg</strong>:</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Weight</p></td><td style="vertical-align:top"><p>Starting dose: 0.1 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.2 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.3 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.4 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Maximum recommended dose: 0.5 ml/kg</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>20 kg</p></td><td style="vertical-align:top"><p>2 ml</p></td><td style="vertical-align:top"><p>4 ml</p></td><td style="vertical-align:top"><p>6 ml</p></td><td style="vertical-align:top"><p>8 ml</p></td><td style="vertical-align:top"><p>10 ml</p></td></tr><tr><td style="vertical-align:top"><p>25 kg</p></td><td style="vertical-align:top"><p>2.5 ml</p></td><td style="vertical-align:top"><p>5 ml</p></td><td style="vertical-align:top"><p>7.5 ml</p></td><td style="vertical-align:top"><p>10 ml</p></td><td style="vertical-align:top"><p>12.5 ml</p></td></tr></tbody></table><p>&nbsp;</p><p>In children from 4&nbsp;years of age with a body weight of 30 to under 50&nbsp;kg:</p><ul><li>the usual starting dose is 1&nbsp;mg (0.1&nbsp;ml), for each kilogram (kg) of body weight, twice a day.</li></ul><p>&nbsp;</p><p>Your doctor may then increase your twice daily dose every week by 1&nbsp;mg (0.1&nbsp;ml) for each kg of body weight. This will be until you reach a maintenance dose. The maximum recommended dose is 4&nbsp;mg (0.4&nbsp;ml), for each kg of body weight, twice a day. A dosing chart is provided below.</p><p>&nbsp;</p><p>Taking Vimpat with other antiepileptic medicines - <strong>Children and adolescents with a body weight of 30&nbsp;kg to under 50&nbsp;kg - </strong>This is for information only. Your doctor will work out the right dose for you:</p><p>&nbsp;</p><p><strong>To be taken twice daily</strong> for children and adolescents from 4 years of age <strong>weighing 30&nbsp;kg to under 50&nbsp;kg</strong>:</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Weight</p></td><td style="vertical-align:top"><p>Starting dose: 0.1 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.2 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.3 ml/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Maximum recommended dose: 0.4 ml/kg</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>30 kg</p></td><td style="vertical-align:top"><p>3 ml</p></td><td style="vertical-align:top"><p>6 ml</p></td><td style="vertical-align:top"><p>9 ml</p></td><td style="vertical-align:top"><p>12 ml</p></td></tr><tr><td style="vertical-align:top"><p>35 kg</p></td><td style="vertical-align:top"><p>3.5 ml</p></td><td style="vertical-align:top"><p>7 ml</p></td><td style="vertical-align:top"><p>10.5 ml</p></td><td style="vertical-align:top"><p>14 ml</p></td></tr><tr><td style="vertical-align:top"><p>40 kg</p></td><td style="vertical-align:top"><p>4 ml</p></td><td style="vertical-align:top"><p>8 ml</p></td><td style="vertical-align:top"><p>12 ml</p></td><td style="vertical-align:top"><p>16 ml</p></td></tr><tr><td style="vertical-align:top"><p>45 kg</p></td><td style="vertical-align:top"><p>4.5 ml</p></td><td style="vertical-align:top"><p>9 ml</p></td><td style="vertical-align:top"><p>13.5 ml</p></td><td style="vertical-align:top"><p>18 ml</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><strong>Instructions for use: measuring cup</strong></p><p><u>&nbsp;</u></p><p><strong>Adolescents</strong><strong> and children weighing 50</strong>&nbsp;<strong>kg or more </strong><strong>and</strong><strong><em> </em></strong><strong>adults</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use the measuring cup provided in this pack.</p><p>1. Shake the bottle well before use.</p><p>2. Fill the measuring cup to the millilitre (ml) dose marker prescribed by your doctor.</p><p>3. Swallow the dose of syrup.</p><p>4. Then drink some water.</p><p><em>&nbsp;</em></p><p>&nbsp;</p><p><strong>Instructions for use: oral syringe</strong></p><p><strong>&nbsp;</strong></p><p>Your doctor will show you how to use the oral syringe, before you use it for the first time. If you have any questions, please go back to your doctor or pharmacist.</p><p><strong>&nbsp;</strong></p><p><strong>Children and </strong><strong>adolescents weighing less than 50&nbsp;kg </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use the oral syringe and the adaptor provided in this pack.</p><p>&nbsp;</p><p>Shake the bottle well before use.</p><p>Open the bottle by pressing the cap while turning it anti-clockwise (figure 1).</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:121.5pt;height:121.5pt;visibility:visible'>
 <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="162" height="162" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image002.jpg" /></p><p>&nbsp;</p><p>Follow these steps the first time you take Vimpat:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take off the adaptor from the oral syringe (figure 2).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Put the adaptor into the top of the bottle (figure 3). Make sure it is fixed well in place. You do not need to remove the adaptor after use.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape
 id="_x0000_i1026" type="#_x0000_t75" style='width:122.25pt;height:124.5pt;
 visibility:visible'>
 <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image003.png"
  o:title=""/>
</v:shape><![endif]--><img width="163" height="166" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image004.jpg" /><!--[if gte vml 1]><v:shape id="_x0000_i1027"
 type="#_x0000_t75" style='width:124.5pt;height:125.25pt;visibility:visible'>
 <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image005.png"
  o:title=""/>
</v:shape><![endif]--><img width="166" height="167" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image006.jpg" /></p><p>&nbsp;</p><p>Follow these steps each time you take Vimpat:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Put the oral syringe into the adaptor opening (figure 4).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turn the bottle upside down (figure 5).</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape
 id="_x0000_i1028" type="#_x0000_t75" style='width:123pt;height:123pt;
 visibility:visible'>
 <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image007.png"
  o:title=""/>
</v:shape><![endif]--><img width="164" height="164" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image008.jpg" /><!--[if gte vml 1]><v:shape id="_x0000_i1029"
 type="#_x0000_t75" style='width:124.5pt;height:123pt;visibility:visible'>
 <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image009.png"
  o:title=""/>
</v:shape><![endif]--><img width="166" height="164" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image010.jpg" /></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hold the bottle upside down in one hand and use the other hand to fill the oral syringe.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pull the piston down to fill the oral syringe with a small amount of solution (figure 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Push the piston up to get rid of any bubbles (figure 7).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pull the piston down to the millilitre (ml) dose marker prescribed by your doctor (figure 8).</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape
 id="_x0000_i1030" type="#_x0000_t75" style='width:191.25pt;height:125.25pt;
 visibility:visible'>
 <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image011.png"
  o:title=""/>
</v:shape><![endif]--><img width="255" height="167" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image012.jpg" /><!--[if gte vml 1]><v:shape id="_x0000_i1031"
 type="#_x0000_t75" style='width:121.5pt;height:123pt;visibility:visible'>
 <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image013.png"
  o:title=""/>
</v:shape><![endif]--><img width="162" height="164" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image014.jpg" />&nbsp;<!--[if gte vml 1]><v:shape
 id="_x0000_i1032" type="#_x0000_t75" style='width:123pt;height:124.5pt;
 visibility:visible'>
 <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image015.png"
  o:title=""/>
</v:shape><![endif]--><img width="164" height="166" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image016.jpg" /></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turn the bottle the right way up (figure 9).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take the oral syringe out of the adaptor (figure 10).</p><p><em>&nbsp;</em></p><p><!--[if gte vml 1]><v:shape id="_x0000_i1033" type="#_x0000_t75"
 style='width:123pt;height:189.75pt;visibility:visible'>
 <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image017.png"
  o:title=""/>
</v:shape><![endif]--><img width="164" height="253" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image018.jpg" /><!--[if gte vml 1]><v:shape id="_x0000_i1034"
 type="#_x0000_t75" style='width:124.5pt;height:124.5pt;visibility:visible'>
 <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image019.png"
  o:title=""/>
</v:shape><![endif]--><img width="166" height="166" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image020.jpg" /></p><p>&nbsp;</p><p>There are two ways in which you can choose to drink the medicine:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; empty the contents of the oral syringe into a little water by pushing the piston to the bottom of the oral syringe (figure 11) &ndash; you will then need to drink all of the water (add just enough to make it easy to drink) <strong><u>or</u></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drink the solution directly from the oral syringe without water (figure 12) &ndash; drink the whole contents of the oral syringe.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape
 id="_x0000_i1035" type="#_x0000_t75" style='width:124.5pt;height:124.5pt;
 visibility:visible'>
 <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image021.png"
  o:title=""/>
</v:shape><![endif]--><img width="166" height="166" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image022.jpg" /><!--[if gte vml 1]><v:shape id="_x0000_i1036"
 type="#_x0000_t75" style='width:125.25pt;height:123.75pt;visibility:visible'>
 <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image023.png"
  o:title=""/>
</v:shape><![endif]--><img width="167" height="165" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image024.jpg" /></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Close the bottle with the plastic screw cap (you do not need to remove the adaptor).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wash the oral syringe with water only (figure 13).</p><p><!--[if gte vml 1]><v:shape
 id="_x0000_i1037" type="#_x0000_t75" style='width:124.5pt;height:124.5pt;
 visibility:visible'>
 <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image025.png"
  o:title=""/>
</v:shape><![endif]--><img width="166" height="166" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image026.jpg" /></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>If you take more Vimpat than you should </strong></p><p>If you have taken more Vimpat than you should, contact your doctor immediately. Do not try to drive.</p><p>You may experience:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea) or being sick (vomiting);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fits (seizures), heart beat problems such as a slow, fast or irregular heart beat, coma or a fall in blood pressure with rapid heartbeat and sweating.</p><p>&nbsp;</p><p><strong>If you forget to take Vimpat </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have missed a dose within the first 6&nbsp;hours of the scheduled dose, take it as soon as you remember.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have missed a dose beyond the first 6&nbsp;hours of the scheduled dose, do not take the missed syrup anymore. Instead take Vimpat at the next time that you would normally take it.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take a double dose to make up for a forgotten dose.</p><p><strong>&nbsp;</strong></p><p><strong>If you stop taking Vimpat</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not stop taking Vimpat without talking to your doctor, as your epilepsy may come back again or become worse.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your doctor decides to stop your treatment with Vimpat, they will tell you how to decrease the dose step by step.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible side effects</strong></p><p>&nbsp;</p><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Nervous system side effects such as dizziness may be higher after a single &ldquo;loading&rdquo; dose.</p><p><strong>&nbsp;</strong></p><p><strong>Talk to your doctor or pharmacist if you get any of the following:</strong></p><p>&nbsp;</p><p><strong>Very common</strong>: may affect more than 1 in 10&nbsp;people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling dizzy or sick (nausea);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Double vision (diplopia).</p><p>&nbsp;</p><p><strong>Common</strong>: may affect up to 1 in 10&nbsp;people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problems in keeping your balance, shaking (tremor), tingling (paresthesia) or muscle spasms, falling easily and getting bruises;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Trouble with your memory, thinking or finding words, confusion;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rapid and uncontrollable movements of the eyes (nystagmus), blurred vision;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A spinning sensation (vertigo), feeling drunk;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Being sick (vomiting), dry mouth, constipation, indigestion, excessive gas in the stomach or bowel, diarrhoea;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased feeling or sensitivity, difficulty in articulating words, disturbance in attention;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Noise in the ear such as buzzing, ringing or whistling;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irritability, trouble sleeping, depression;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sleepiness, tiredness or weakness (asthenia);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching, rash.</p><p><strong>&nbsp;</strong></p><p><strong>Uncommon</strong>: may affect up to 1 in 100&nbsp;people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Slow heart rate, palpitations, irregular pulse or other changes in the electrical activity of your heart (conduction disorder);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exaggerated feeling of wellbeing, seeing and/or hearing things which are not there;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reaction to medicine intake, hives;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood tests may show abnormal liver function, liver injury;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thoughts of harming or killing yourself or attempting suicide: tell your doctor straight away;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling angry or agitated;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal thinking or losing of touch with reality;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious allergic reaction which causes swelling of the face, throat, hands, feet, ankles, or lower legs;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fainting;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulties in coordinating your movements or walking.</p><p>&nbsp;</p><p><strong>Not known</strong>: frequency cannot be estimated from available data</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal rapid heartbeat (ventricular tachyarrhythmia);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A sore throat, high temperature and getting more infections than usual. Blood tests may show a severe decrease in a specific class of white blood cells (agranulocytosis);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A serious skin reaction which may include a high temperature and other flu-like symptoms, a rash on the face, extended rash, swollen glands (enlarged lymph nodes). Blood tests may show increased levels of liver enzymes and a type of white blood cell (eosinophilia);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens&ndash;Johnson syndrome), and a more severe form causing skin peeling in more than 30&nbsp;% of the body surface (toxic epidermal necrolysis);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Convulsion.</p><p>&nbsp;</p><p><strong>Additional side effects in children </strong></p><p>&nbsp;</p><p><strong>Common: </strong>may affect up to 1 in 10&nbsp;children</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Runny nose (nasopharyngitis);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever (pyrexia);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sore throat (pharyngitis);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eating less than usual.</p><p>&nbsp;</p><p><strong>Uncommon</strong>: may affect up to 1 in 100&nbsp;children</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sleepy or lacking in energy (lethargy).</p><p>&nbsp;</p><p><strong>Not known: </strong>frequency cannot be estimated from available data</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in behaviour, not acting like themselves.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to store Vimpat </strong></p><p>&nbsp;</p><p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and bottle after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not store above 30&deg;C</p><p>Do not refrigerate.</p><p>Once you have opened the syrup bottle, do not use<u> beyond 2&nbsp;months</u>.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents of the pack and other information</strong></p><p>&nbsp;</p><p><strong>What Vimpat contains</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is lacosamide. 1&nbsp;ml Vimpat syrup contains 10&nbsp;mg lacosamide.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are glycerol (E422), carmellose sodium, sorbitol liquid (crystallizing) (E420), polyethylene glycol 4000, sodium chloride, citric acid anhydrous, acesulfame potassium (E950), sodium methyl parahydroxybenzoate (E219), strawberry flavour (contains propylene glycol, maltol), masking flavour (contains propylene glycol, aspartame (E951), acesulfame potassium (E950), maltol, deionised water), purified water.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Vimpat looks like and contents of the pack

·                     Vimpat 10 mg/ml syrup is a slightly viscous clear, colourless to yellow-brown liquid.

·                     Vimpat is available in a bottle of 200 ml.



The carton boxes of Vimpat syrup contain a 30 ml measuring cup with graduation marks and a 10 ml oral syringe.

·                     The measuring cup is suitable for adults, adolescents and children weighing 50 kg and above. Each graduation mark (5 ml) of the measuring cup corresponds to 50 mg of lacosamide (for example 2 graduation marks correspond to 100 mg).

·                     The oral syringe is suitable for children and adolescents below 50 kg. One full 10 ml oral syringe corresponds to 100 mg of lacosamide. The minimum extractable volume is 1 ml, which is 10 mg of lacosamide. After this, each graduation mark (0.25 ml) corresponds to 2.5 mg of lacosamide (for example 4 graduation marks corresponds to 10 mg).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder </strong></p><p>UCB Pharma S.A., All&eacute;e de la Recherche 60, B‑1070 Bruxelles, Belgium.</p><p>&nbsp;</p><p><strong>Batch releaser</strong></p><p>Aesica Pharmaceuticals GmbH, Alfred-Nobel Strasse 10, D-40789 Monheim am Rhein, Germany.</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Unither Manufacturing, LLC, 331 Clay Road (755 Jefferson Road), Rochester, NY 14623, USA</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	This leaflet was last revised in {09/201706/2019 }.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>1. ما هو دواء ڨيمبات؟ وفيم يُستخدم؟</strong></p><p dir="RTL"><strong>ما هو دواء ڨيمبات؟</strong></p><p dir="RTL">يحتوي دواء ڨيمبات على لاكوساميد.&nbsp; ينتمي هذا الدَّواء إلى مجموعة من الأدوية تسمى: &quot;مضادات الصرع&quot;. تستخدم هذه الأدوية في علاج الصرع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لقد تم إعطاؤك هذا الدَّواء لخفض عدد التشنجات (النوبات التشنُّجية) التي تتعرَّض لها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>فيم يُستخدم دواء ڨيمبات؟</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُستخدم دواء ڨيمبات في البالغين والمراهقين والأطفال من عمر 4 سنوات وأكثر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُستخدم لعلاج نوع معين من أنواع الصرع &nbsp;يتسم بحدوث نوبة تشنجية تظهر جزئيًّا مع تعميم ثانوي أو بدونه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في هذا النوع من الصَّرَع، تؤثر التشنجات أولًا على أحد جانبي المخ. مع ذلك، قد تنتشر بعد ذلك لتصيب مناطق أكبر على كلا جانبي المخ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُمكِن استخدام دواء ڤيمبات بمفرده أو مع مضادات الصَّرَع الأخرى.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>2. </strong><strong>ما الذي تحتاج إلى معرفته قبل تناول دواء ڨيمبات؟</strong></p><p dir="RTL"><strong>لا تتناول دواء ڨيمبات</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت مصابًا بالحساسية تجاه مادة لاكوساميد أو أي من المكونات الأخرى لهذا الدواء &nbsp;)مدرجة في القسم السادس(. إذا كنت غير متأكد من أنك مُصاب بالحساسية، الرجاء مناقشة الأمر مع الطبيب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك نوع محدد من المشاكل المتعلقة بضربات القلب يُسمى &nbsp;الإحصار الأذيني البطيني من الدرجة الثانية أو الثالثة.</p><p dir="RTL">لا تتناول دواء ڨيمبات إذا كان أي مما سبق ينطبق عليك. إذا لم تكن متأكدًا، تحدَّث مع طبيبك أو الصيدلي الخاص بك قبل تناول هذا الدَّواء.</p><p dir="RTL"><strong>التحذيرات</strong><strong> </strong><strong>والاحتياطات</strong></p><p dir="RTL">تحدث إلى الطبيب قبل أخذ دواء ڨيمبات في الحالات الآتية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك أفكار لإيذاء نفسك أو قتلها. قد عانى عدد قليل من الأشخاص الذين يتم علاجهم بالمنتجات الدَّوائية المضادة للصرع مثل: لاكوساميد من أفكار لإيذاء أو قتل أنفسهم. إذا كان لديك أيٌّ من هذه الأفكار في أي وقت، فأخبر طبيبك فورًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشكلة بالقلب تُؤثر على ضربات القلب لديك وغالبًا ما تعاني من ضربات قلب بطيئة على وجه الخصوص أو سريعة أو غير منتظمة (مثل: الإحصار الأذيني البطيني، الرجفان الأذيني أو الرفرفة الأذينية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض قلبي شديد مثل هبوط (فشل) القلب أو كنت قد أُصبت بنوبة قلبية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت في كثير من الأحيان تشعر بالدوخة أو تتعرَّض للسقوط.<strong> </strong>قد يجعلك دواء ڨيمبات تشعر بدوخة- وهذا قد يرفع خطر حدوث إصابة عرضية أو سقوط. هذا يعني أنه عليك توخي الحذر حتى تعتاد على تأثيرات هذا الدَّواء.</p><p dir="RTL">إذا كان أي مما سبق ينطبق عليك (أو إذا لم تكن متأكدًا مما سبق)، تحدَّث إلى طبيبك أو الصيدلي الخاص بك قبل تناول دواء ڨيمبات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تتناول دواء ڤيمبات وتعاني من أعراض دقات قلب غير طبيعية (مثل ضربات قلب بطيئة أو سريعة أو غير منتظمة، خفقان، ضيق النفس، الشعور بالدوار، الإغماء)، فاطلب المشورة الطبية فورًا (انظر القسم 4).</p><p dir="RTL"><strong>الأطفال</strong> &nbsp;<strong>الأقل من 4 سنوات</strong></p><p dir="RTL">لا يوصى باستعمال ڨيمبات للأطفال والمراهقين الذين تقل أعمارهم عن 4 سنوات. هذا لأننا لم نعلم بعد ما إذا كان سيعمل أم لا، وما إذا كان آمنًا على الأطفال في هذه الفئة العُمْرية أم لا.</p><p dir="RTL"><strong>تناوُل</strong><strong> </strong><strong>الأدوية</strong><strong> </strong><strong>الأخرى</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>دواء</strong><strong> </strong><strong>ڨيمبات</strong></p><p dir="RTL">يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى.&nbsp;</p><p dir="RTL">وعلى وجه الخصوص، أخبر طبيبك أو الصيدلي الخاص بك إذا كنت تتناول أيًّا من الأدوية التَّالية التي تؤثر على القلب لديك- هذا لأنَّ دواء ڨيمبات قد يُؤثر أيضًا على القلب لديك:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تُستخدم لعلاج مشاكل القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي قد تُزيد &quot;فاصل PR&quot; على فحص القلب (مُخَطط كهربية القلب) مثل:&nbsp; أدوية علاج الصَّرَع أو الألم التي تُسمى كاربامازيبين أو لاموترجين أو بريجابالين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تُستخدم لعلاج أنواع معينة من عدم انتظام ضربات القلب أو فشل القلب.</p><p dir="RTL">إذا كان أي مما سبق ينطبق عليك (أو إذا لم تكن متأكدًا مما سبق)، تحدَّث إلى طبيبك أو الصيدلي الخاص بك قبل تناول دواء ڨيمبات.</p><p dir="RTL">أيضًا، أخبر طبيبك أو الصيدلي الخاص بك إذا كنت تتناول أيًّا من الأدوية التَّالية. وذلك بسبب أنها قد تزيد أو تخفض من تأثير دواء ڨيمبات في جسمك:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة في علاج العدوى الفطرية التي تُسمى فلوكونازول أو إتراكونازول أو كيتوكونازول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أحد أدوية علاج فيروس نقص المناعة البشرية الذي يُسمى ريتونافير.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة في علاج العدوى البكتيرية التي تُسمى كلاريثروميسين أو إريثروميسين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء عشبي يُستَخدَم لعلاج الحالات الطفيفة من القلق والاكتئاب يُسمى نبتة سانت جونز.</p><p dir="RTL">إذا كان أي مما سبق ينطبق عليك (أو إذا لم تكن متأكدًا مما سبق)، تحدَّث إلى طبيبك أو الصيدلي الخاص بك قبل تناول دواء ڨيمبات.</p><p dir="RTL"><strong>تناول</strong><strong> </strong><strong>دواء</strong><strong> </strong><strong>ڨيمبات</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>الكحول</strong></p><p dir="RTL">كأحد احتياطات الأمان لا تتناول ڨيمبات مع الكحول.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنتِ حاملاً أو مرضعة أو تظنين أنكِ حامل أو تخططين لإنجاب طفل، فاستشيرى طبيبكِ أو الصيدلي الخاص بكِ قبل تناول هذا الدواء.</p><p dir="RTL">يُوصى بعدم تناول دواء ڨيمبات إذا كنتِ حاملًا أو مرضعًا؛ إذ إن تأثيرات دواء ڨيمبات على الحمل وعلى الجنين وعلى الطفل حديث الولادة غير معروفة. أيضًا، من غير المعروف ما إذا كان يمر دواء ڨيمبات إلى لبن الأم أم لا. اطلبي المشورة فورًا من طبيبكِ إذا أصبحتِ حاملًا أو كنت تخططين للحَمْل. سيُساعِدونكِ على اتخاذ قرار بشأن ما إذا كان عليكِ تناوُل دواء ڨيمبات أم لا.</p><p dir="RTL">يجب أَلَّا تتوقف عن العلاج دون التَّحدث إلى طبيبك أولًا لأنَّ ذلك قد يزيد من حدوث التشنجات التي تعاني منها (النوبات التشنجية). قد يُؤدي تفاقم المرض لديكِ أيضًا إلى إلحاق الضرر بطفلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة</strong><strong> </strong><strong>واستخدام</strong><strong> </strong><strong>الماكينات</strong></p><p dir="RTL">لا تمارس قيادة المركبات أو ركوب الدراجات أو تستخدم أي أدوات أو آلات حتى تعرف كيفية تأثير هذا الدَّواء عليك. هذا لأنَّ دواء ڨيمبات قد يجعلك تشعر بالدوخة أو يسبب لك عدم وضوح بالرؤية.</p><p dir="RTL"><strong>ڨيمبات يحتوى على</strong> <strong>سوربيتول و صوديوم و ميثيل بارا هيدروكسي بنزوات الصوديوم و أسبارتام</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سوربيتول &nbsp;)نوع من السكر(: إذا أخبرك الطبيب بعدم تحملك لبعض أنواع السكر، فاتصل بالطبيب قبل أخذ ذلك الدواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصوديوم (ملح):</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;هناك 7.09 ملغم صوديوم في كل علامة تدرج (5 ملل) لكوب القياس. إذا تناولت أكثر من ثلاث علامات تدريج من الشراب يوميًّا، وكنت تتبع نظامًا غذائيًّا منخفض الصوديوم، فعليك أن تأخذ ذلك بالاعتبار.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هناك 3.5 ملغم صوديوم في كل جرعة قدرها 2.5 ملل &nbsp;من السرنجة الفموية. إذا تناولت أكثر من 12.5 ملل من الشراب كل يوم وكنت تتبع نظامًا غذائيًّا منخفض الصوديوم، فخذ ذلك في الاعتبار.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميثيل بارا هيدروكسي بنزوات الصوديوم (E219) يمكن أن يتسبب في حدوث تفاعلات حساسية &nbsp;) قد تتأخر (.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أسبارتام (E951): وهو أحد مصادر الفينيل ألانين. مما قد يضر بالأشخاص المصابين ببيلَة الفينيل كيتون &nbsp;)مرض استقلابي نادر (.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>3.كيفية</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>دواء</strong><strong> </strong><strong>ڨيمبات</strong></p><p dir="RTL">&nbsp;تناول دائمًا هذا الدَّواء بالضبط كما أخبرك طبيبك أو الصيدلي الخاص بك. يرجى مراجعة طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكدًا تمامًا.</p><p dir="RTL"><strong>تناوُل دواء ڨيمبات</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول دواء ڨيمبات مرَّتين كل يوم- مرّة في الصباح وأخرى في المساء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاول أن تتناول الدواء في نفس الوقت تقريبًا من كل يوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكنك تناول دواء ڨيمبات مع الطعام أو دونه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ستبدأ عادة بتناول جرعة منخفضة كل يوم وسيزيد طبيبك ببطء هذه الجرعة على مدار عدة أسابيع. عندما تصل إلى الجرعة المناسبة لك، تُسمى هذه &quot;جرعة المداومة&quot;، ستتناول بعدها الكمية نفسها كل يوم. يُستخدم دواء ڨيمبات كعلاج طويل الأمد. يجب عليك الاستمرار في تناول دواء ڨيمبات إلى أن يخبرك طبيبك بالتَّوقف عن تناوله.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما هي الكمية التي يجب أن تتناولها؟</strong></p><p dir="RTL">مدرج أدناه الجرعات المعتادة الموصى بها لدواء ڨيمبات للفئات العمرية والأوزان المختلفة. قد يصف لك طبيبك جرعة مختلفة إذا كنت تعاني من مشاكل بالكلى أو الكبد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المراهقون والأطفال الذين يزنون 50</strong>&nbsp;<strong> كجم أو أكثر</strong> <strong>والبالغون</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُستَخدَم كوب القياس المتوفر في العبوة الكرتونية.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>عند تناوُلك لدواء ڨيمبات بمفرده</u></p><p dir="RTL">جرعة البدء المعتادة من دواء ڨيمبات هي 50 ملغم (5 ملل) مرّتين في اليوم.</p><p dir="RTL">قد يصف لك طبيبك أيضًا جرعة بدء قدرها 100 ملغم (10 ملل) من دواء ڨيمبات مرتين في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يرفع طبيبك جرعتك التي تتناولها مرَّتين يوميًّا كل أسبوع بمقدار 50 ملغم (5 ملل). سيتم ذلك حتى تصل إلى جرعة مداومة تتراوح بين 100 ملغم (10 ملل) و300 ملغم (30 ملل) مرَّتين في اليوم.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>عند تناولك دواء ڨيمبات مع مضادات الصَّرَع الأخرى</u></p><p dir="RTL">جرعة البدء المعتادة من دواء ڨيمبات هي 50 ملغم (5 ملل) مرّتين في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يرفع طبيبك جرعتك التي تتناولها مرَّتين يوميًّا كل أسبوع بمقدار 50 ملغم (5 ملل). سيتم ذلك حتى تصل إلى جرعة مداومة تتراوح بين 100 ملغم (10 ملل) و200 ملغم (20 ملل) مرَّتين في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يقرر طبيبك بدء العلاج بدواء ڨيمبات بجرعة &quot;تحميل&quot;&nbsp; مفردة قدرها 200 ملغم (20 ملل)، إذا كنت تزن 50 كجم أو أكثر. سوف تبدأ بعد ذلك في تناول جرعة المداومة المستمرة الخاصَّة بك بعد 12 ساعة.</p><p dir="RTL"><strong>الأطفال والمراهقون الذين تقل أوزانهم عن 50</strong>&nbsp;<strong> كجم</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تُستَخدَم السرنجة الفموية المتوفرة في العبوة الكرتونية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>عند تناوُلك لدواء ڨيمبات بمفرده</u></p><p dir="RTL">سوف يقرر طبيبك جرعة دواء ڨيمبات وفقًا لوزن جسمك.</p><p dir="RTL">جرعة البدء المعتادة هي 1 ملغم (0.1 ملل)، لكل كجم من وزن الجسم، مرتين في اليوم.&nbsp;</p><p dir="RTL">قد يرفع طبيبك بعد ذلك جرعتك التي تتناولها مرَّتين&nbsp; يوميًّا كل أسبوع بمقدار 1 ملغم (0.1 ملل) لكل كجم من وزن جسمك. سيتم ذلك حتى تصل إلى جرعة المداومة. الجرعة القُصوى المُوصى بها هي 6 ملغم (0.6 ملل) لكل كجم من وزن الجسم، مرّتين في اليوم، بالنسبة إلى الأطفال الذين تقل أوزانهم عن 40 كجم. الجرعة القُصوى المُوصى بها هي 5 ملغم (0.5 ملل) لكل كجم من وزن الجسم، مرّتين في اليوم، بالنسبة إلى الأطفال الذين تتراوح أوزانهم بين 40 كجم وأقل من 50 كجم. وارد أدناه مُخَططات الجرعات:</p><p dir="RTL">تناوُل دواء ڨيمبات يكون بمفرده - هذا للعلم فقط. سيتولى طبيبك تحديد الجرعة المناسبة لك.<strong> </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يتم تناوله مرتين يوميًّا</strong> بالنسبة للأطفال اعتبارًا من عمر 4 سنوات <strong>الذين تقل أوزانهم عن 40 كجم</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">الوزن</p></td><td style="vertical-align:top"><p dir="RTL">جرعة البدء: 0.1 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">0.2 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">0.3 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">0.4 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">0.5 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">أقصى جرعة موصى بها: 0.6 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">10 كجم</p></td><td style="vertical-align:top"><p dir="RTL">1 ملل</p></td><td style="vertical-align:top"><p dir="RTL">2 ملل</p></td><td style="vertical-align:top"><p dir="RTL">3 ملل</p></td><td style="vertical-align:top"><p dir="RTL">4 ملل</p></td><td style="vertical-align:top"><p dir="RTL">5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">6 ملل</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">15 كجم</p></td><td style="vertical-align:top"><p dir="RTL">1.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">3 ملل</p></td><td style="vertical-align:top"><p dir="RTL">4.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">6 ملل</p></td><td style="vertical-align:top"><p dir="RTL">7.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">9 ملل</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">20 كجم</p></td><td style="vertical-align:top"><p dir="RTL">2 ملل</p></td><td style="vertical-align:top"><p dir="RTL">4 ملل</p></td><td style="vertical-align:top"><p dir="RTL">6 ملل</p></td><td style="vertical-align:top"><p dir="RTL">8 ملل</p></td><td style="vertical-align:top"><p dir="RTL">10 ملل</p></td><td style="vertical-align:top"><p dir="RTL">12 ملل</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">25 كجم</p></td><td style="vertical-align:top"><p dir="RTL">2.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">7.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">10 ملل</p></td><td style="vertical-align:top"><p dir="RTL">12.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">15 ملل</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">30 كجم</p></td><td style="vertical-align:top"><p dir="RTL">3 ملل</p></td><td style="vertical-align:top"><p dir="RTL">6 ملل</p></td><td style="vertical-align:top"><p dir="RTL">9 ملل</p></td><td style="vertical-align:top"><p dir="RTL">12 ملل</p></td><td style="vertical-align:top"><p dir="RTL">15 ملل</p></td><td style="vertical-align:top"><p dir="RTL">18 ملل</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">35 كجم</p></td><td style="vertical-align:top"><p dir="RTL">3.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">7 ملل</p></td><td style="vertical-align:top"><p dir="RTL">10.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">14 ملل</p></td><td style="vertical-align:top"><p dir="RTL">17.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">21 ملل</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يتم تناوله مرتين يوميًّا</strong> بالنسبة للأطفال والمراهقين اعتبارًا من عمر 4 سنوات <strong>الذين تتراوح أوزانهم بين 40 كجم وأقل من 50 كجم:</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL">الوزن</p></td><td style="vertical-align:top"><p dir="RTL">جرعة البدء: 0.1 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">0.2 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">0.3 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">0.4 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">أقصى جرعة موصى بها: 0.5 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">40 كجم</p></td><td style="vertical-align:top"><p dir="RTL">4 ملل</p></td><td style="vertical-align:top"><p dir="RTL">8 ملل</p></td><td style="vertical-align:top"><p dir="RTL">12 ملل</p></td><td style="vertical-align:top"><p dir="RTL">16 ملل</p></td><td style="vertical-align:top"><p dir="RTL">20 ملل</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">45 كجم</p></td><td style="vertical-align:top"><p dir="RTL">4.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">9 ملل</p></td><td style="vertical-align:top"><p dir="RTL">13.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">18 ملل</p></td><td style="vertical-align:top"><p dir="RTL">22.5 ملل</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><u>عند تناول دواء ڨيمبات مع مضادات الصَّرَع الأخرى</u></p><p dir="RTL">سوف يقرر طبيبك جرعة دواء ڨيمبات وفقًا لوزن جسمك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في الأطفال من سن 4 سنوات الذين تقل أوزانهم عن 20 كجم:</p><ul><li dir="RTL">جرعة البدء المعتادة هي 1 ملغم (0.1 ملل)، لكل كجم من وزن الجسم، مرتين في اليوم.&nbsp;</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">قد يرفع طبيبك بعد ذلك جرعتك التي تتناولها مرَّتين يوميًّا كل أسبوع بمقدار 1 ملغم (0.1 ملل) لكل كجم من وزن جسمك. سيتم ذلك حتى تصل إلى جرعة المداومة. الجرعة القصوى الموصى بها هي 6 ملغم (0.6 ملل)، لكل كجم من وزن الجسم، مرتين في اليوم. وارد أدناه مخطط الجرعات.</p><p dir="RTL">&nbsp;تناوُل دواء ڨيمبات مع الأدوية الأخرى المضادة للصَّرَع - <strong>الأطفال الذين تزيد أعمارهم عن 4 سنوات وتقل أوزانهم عن 20</strong>&nbsp;<strong> كجم</strong> - هذا للعلم فقط. سيتولى طبيبك تحديد الجرعة المناسبة لك.</p><p dir="RTL"><strong>يتم تناوُله مرّتين يوميًّا </strong>بالنسبة للأطفال من عمر 4 سنوات <strong>الذين تقل أوزانهم</strong> <strong>عن 20 كجم</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">الوزن</p></td><td style="vertical-align:top"><p dir="RTL">جرعة البدء: 0.1 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">0.2 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">0.3 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">0.4 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">0.5 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">أقصى جرعة موصى بها: 0.6 ملل/ كجم</p><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">10 كجم</p></td><td style="vertical-align:top"><p dir="RTL">1 ملل</p></td><td style="vertical-align:top"><p dir="RTL">2 ملل</p></td><td style="vertical-align:top"><p dir="RTL">3 ملل</p></td><td style="vertical-align:top"><p dir="RTL">4 ملل</p></td><td style="vertical-align:top"><p dir="RTL">5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">6 ملل</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">15 كجم</p></td><td style="vertical-align:top"><p dir="RTL">1.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">3 ملل</p></td><td style="vertical-align:top"><p dir="RTL">4.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">6 ملل</p></td><td style="vertical-align:top"><p dir="RTL">7.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">9 ملل</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">في الأطفال من عمر 4 سنوات الذين تتراوح أوزانهم بين 20 وأقل من 30 كجم:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جرعة البدء المعتادة هي 1 ملغم (0.1 ملل)، لكل كجم من وزن الجسم، مرتين في اليوم.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يرفع طبيبك بعد ذلك جرعتك التي تتناولها مرَّتين يوميًّا كل أسبوع بمقدار 1 ملغم (0.1 ملل ) لكل كجم من وزن جسمك. سيتم ذلك حتى الوصول إلى جرعة المداومة. الجرعة القصوى الموصى بها هي 5 ملغم (0.5 ملل )، لكل كجم من وزن الجسم، مرتين في اليوم. وارد أدناه مخطط الجرعات.</p><p dir="RTL">تناوُل دواء ڨيمبات مع الأدوية الأخرى المضادة للصَّرَع - <strong>الأطفال والمراهقون ممن تتراوح أوزانهم بين 20 كجم وأقل من 30 كجم</strong> - هذا للعلم فقط. سيتولى طبيبك تحديد الجرعة المناسبة لك.</p><p dir="RTL"><strong>يتم تناوله مرتين يوميًّا</strong> بالنسبة للأطفال والمراهقين اعتبارًا من عمر 4 سنوات <strong>الذين تتراوح أوزانهم بين 20 كجم وأقل من 30 كجم:</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL">الوزن</p></td><td style="vertical-align:top"><p dir="RTL">جرعة البدء: 0.1 ملل / كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">0.2 ملل / كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">0.3 ملل / كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">0.4 ملل / كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">أقصى جرعة موصى بها: 0.5 ملل / كجم</p><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">20 كجم</p></td><td style="vertical-align:top"><p dir="RTL">2 ملل</p></td><td style="vertical-align:top"><p dir="RTL">4 ملل</p></td><td style="vertical-align:top"><p dir="RTL">6 ملل</p></td><td style="vertical-align:top"><p dir="RTL">8 ملل</p></td><td style="vertical-align:top"><p dir="RTL">10 ملل</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">25 كجم</p></td><td style="vertical-align:top"><p dir="RTL">2.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">7.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">10 ملل</p></td><td style="vertical-align:top"><p dir="RTL">12.5 ملل</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">في الأطفال من عمر 4 سنوات الذين تتراوح أوزانهم بين 30 وأقل من 50 كجم:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جرعة البدء المعتادة هي 1 ملغم (0.1 ملل)، لكل كجم من وزن الجسم، مرتين في اليوم.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يرفع طبيبك بعد ذلك جرعتك التي تتناولها مرَّتين يوميًّا كل أسبوع بمقدار 1 ملغم (0.1 ملل) لكل كجم من وزن جسمك. سيتم ذلك حتى تصل إلى جرعة المداومة. الجرعة القصوى الموصى بها هي 4 ملغم (0.4 ملل)، لكل كجم من وزن الجسم، مرتين في اليوم. وارد أدناه مخطط الجرعات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تناوُل دواء ڨيمبات مع الأدوية الأخرى المضادة للصَّرَع - <strong>الأطفال والمراهقون ممن تتراوح أوزانهم بين 30 كجم وأقل من 50 كجم</strong> - هذا للعلم فقط. سيتولى طبيبك تحديد الجرعة المناسبة لك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يتم تناوله مرتين يوميًّا</strong> بالنسبة للأطفال والمراهقين اعتبارًا من عمر 4 سنوات <strong>الذين تتراوح أوزانهم بين 30 كجم وأقل من 50 كجم:</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL">الوزن</p></td><td style="vertical-align:top"><p dir="RTL">جرعة البدء: 0.1 ملل / كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">0.2 ملل / كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">0.3 ملل / كجم</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">أقصى جرعة موصى بها: 0.4 ملل / كجم</p><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">30 كجم</p></td><td style="vertical-align:top"><p dir="RTL">3 ملل</p></td><td style="vertical-align:top"><p dir="RTL">6 ملل</p></td><td style="vertical-align:top"><p dir="RTL">9 ملل</p></td><td style="vertical-align:top"><p dir="RTL">12 ملل</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">35 كجم</p></td><td style="vertical-align:top"><p dir="RTL">3.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">7 ملل</p></td><td style="vertical-align:top"><p dir="RTL">10.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">14 ملل</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">40 كجم</p></td><td style="vertical-align:top"><p dir="RTL">4 ملل</p></td><td style="vertical-align:top"><p dir="RTL">8 ملل</p></td><td style="vertical-align:top"><p dir="RTL">12 ملل</p></td><td style="vertical-align:top"><p dir="RTL">16 ملل</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">45 كجم</p></td><td style="vertical-align:top"><p dir="RTL">4.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">9 ملل</p></td><td style="vertical-align:top"><p dir="RTL">13.5 ملل</p></td><td style="vertical-align:top"><p dir="RTL">18 ملل</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تعليمات الاستخدام: كوب القياس</strong></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><strong>المراهقون والأطفال الذين يزنون 50 </strong>&nbsp;<strong>كجم أو أكثر</strong><strong><em> </em></strong><strong>والبالغون</strong></p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>يُستَخدَم كوب القياس المتوفر في هذه العبوة.</p><p dir="RTL">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم برَج الزجاجة جيدًا قبل الاستخدام.</p><p dir="RTL">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; املأ كوب القياس حتى علامة تدرُّج الجرعة بالمللي لتر (ملل) وفقًا لوصف طبيبك.</p><p dir="RTL">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابتلع جرعة الشراب.</p><p dir="RTL">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثم اشرب بعض الماء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تعليمات الاستخدام: للسرنجة الفموية</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">سيُريك طبيبك كيفية استخدام السرنجة الفموية، قبل استخدامها لأول مرة. إذا كانت لديك أية أسئلة، فيُرجى الاتصال بطبيبك أو الصيدلي الخاص بك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال و</strong><strong>المراهقون الذين تقل أوزانهم عن 50&nbsp;كجم</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تُستَخدَم السرنجة الفموية والموائم المتوفرين في&nbsp; هذه العبوة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قم برَج الزجاجة جيدًا قبل الاستخدام.&nbsp; &nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">افتح الزجاجة عن طريق الضغط على الغطاء أثناء لفّه ضد اتجاه عقارب الساعة (شكل 1).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_4" o:spid="_x0000_i1027" type="#_x0000_t75"
 style='width:120.75pt;height:121.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="161" height="162" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image002.jpg" /></p><p dir="RTL">&nbsp;</p><p dir="RTL">اتبع هذه الخطوات عند تناوُلك دواء ڨيمبات لأول مرة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انزع الموائم من السرنجة الفموية (شكل 2).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضع الموائم أعلى الزجاجة (شكل 3). تأكَّد من كونه مُثَبَّتًا جيدًا في موضعه. لن تحتاج إلى إزالة الموائم بعد الاستخدام.</p><p dir="RTL"><!--[if gte vml 1]><v:group id="Group_x0020_14" o:spid="_x0000_s1035"
 style='position:absolute;left:0;text-align:left;margin-left:196.3pt;
 margin-top:1.6pt;width:261.65pt;height:125.3pt;z-index:-251658239'
 coordorigin="5366,12805" coordsize="5233,2506" o:gfxdata="UEsDBBQABgAIAAAAIQA0Ev94FAEAAFACAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSSy07DMBBF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==
">
 <v:shape id="Picture_x0020_3" o:spid="_x0000_s1036" type="#_x0000_t75"
  style='position:absolute;left:8151;top:12818;width:2448;height:2491;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQAEqzleAAEAAOYBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
  <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image003.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_4" o:spid="_x0000_s1037" type="#_x0000_t75"
  style='position:absolute;left:5366;top:12805;width:2491;height:2506;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQAEqzleAAEAAOYBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
  <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image004.png"
   o:title=""/>
 </v:shape><w:wrap type="tight"/>
</v:group><![endif]--><img width="349" height="167" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image005.png" /></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">اتبع هذه الخطوات في كل مرة تتناول فيها دواء ڨيمبات:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضع السرنجة الفموية في فتحة الموائم (شكل 4).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اقلب الزجاجة رأسًا على عقب (شكل 5).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:group
 id="Group_x0020_11" o:spid="_x0000_s1032" style='position:absolute;left:0;
 text-align:left;margin-left:188.35pt;margin-top:6.5pt;width:263.5pt;height:123.1pt;
 z-index:-251658238' coordorigin="5207,2813" coordsize="5270,2462" o:gfxdata="UEsDBBQABgAIAAAAIQA0Ev94FAEAAFACAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSSy07DMBBF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">
 <v:shape id="Picture_x0020_6" o:spid="_x0000_s1033" type="#_x0000_t75"
  style='position:absolute;left:5207;top:2813;width:2506;height:2462;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQAEqzleAAEAAOYBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
  <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image006.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_7" o:spid="_x0000_s1034" type="#_x0000_t75"
  style='position:absolute;left:8015;top:2813;width:2462;height:2462;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQAEqzleAAEAAOYBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
  <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image007.png"
   o:title=""/>
 </v:shape><w:wrap type="tight"/>
</v:group><![endif]--><img width="351" height="164" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image008.png" /></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمسك الزجاجة مقلوبة رأسًا على عقب بإحدى يديك واستخدم اليد الأخرى في تعبئة السرنجة الفموية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اسحب المكبس لأسفل لتعبئة السرنجة الفموية بكمية قليلة من المحلول (شكل 6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ادفع المبكس حتى يتم التخلُّص من أيّة فقاعات (شكل 7).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اسحب المكبس لأسفل حتى علامة تدرُّج الجرعة بالمللي لتر (ملل) التي وصفها لك طبيبك (شكل 8).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shape id="Picture_x0020_20" o:spid="_x0000_s1031"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:2.1pt;margin-top:12.35pt;width:123.1pt;height:124.55pt;z-index:251658245;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page'>
 <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image009.png"
  o:title=""/>
 <w:wrap type="tight"/>
</v:shape><![endif]--><img width="164" height="166" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image010.jpg" /><!--[if gte vml 1]><v:shape
 id="Picture_x0020_19" o:spid="_x0000_s1030" type="#_x0000_t75" style='position:absolute;
 left:0;text-align:left;margin-left:135.35pt;margin-top:13.8pt;width:121.7pt;
 height:123.1pt;z-index:251658244;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page'>
 <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image011.png"
  o:title=""/>
 <w:wrap type="tight"/>
</v:shape><![endif]--><img width="162" height="164" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image012.jpg" /><!--[if gte vml 1]><v:shape
 id="Picture_x0020_18" o:spid="_x0000_s1029" type="#_x0000_t75" style='position:absolute;
 left:0;text-align:left;margin-left:260.35pt;margin-top:11.6pt;width:191.5pt;
 height:125.3pt;z-index:-251658237;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page'>
 <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image013.png"
  o:title=""/>
 <w:wrap type="tight"/>
</v:shape><![endif]--><img width="255" height="167" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image014.jpg" /></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اقلب الزجاجة لتصبح على وضعها الصحيح (شكل 9).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخرِج السرنجة الفموية من الموائم (شكل 10).</p><p dir="RTL"><!--[if gte vml 1]><v:shape id="Picture_x0020_22" o:spid="_x0000_s1028"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:274.6pt;margin-top:3.9pt;width:123.1pt;height:165.6pt;z-index:251658247;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page'>
 <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image015.png"
  o:title=""/>
 <w:wrap type="square"/>
</v:shape><![endif]--><img width="164" height="221" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image016.jpg" /></p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shape id="Picture_x0020_21" o:spid="_x0000_s1027"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:135.35pt;margin-top:9pt;width:125.3pt;height:124.55pt;z-index:251658246;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page'>
 <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image017.png"
  o:title=""/>
 <w:wrap type="square"/>
</v:shape><![endif]--><img width="167" height="166" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image018.jpg" /></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">هناك طريقتان يُمكِنك الاختيار منهما لشرب الدَّواء:</p><ul><li dir="RTL">أفرغ محتويات السرنجة الفموية في كمية قليلة من الماء عن طريق دفع المكبس لأسفل السرنجة الفموية (شكل 11) - ستحتاج بعد ذلك لشرب الماء بالكامل (أضِف ما يكفي لتيسير الشرب) <strong><u>أو</u></strong></li><li dir="RTL">اشرب المحلول مباشرةً من السرنجة الفموية بدون ماء (شكل 12) - اشرب محتويات السرنجة الفموية بالكامل.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shape
 id="Picture_x0020_24" o:spid="_x0000_s1026" type="#_x0000_t75" style='position:absolute;
 left:0;text-align:left;margin-left:324.05pt;margin-top:9.45pt;width:125.3pt;
 height:125.3pt;z-index:-251658232;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page'>
 <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image019.png"
  o:title=""/>
 <w:wrap type="tight"/>
</v:shape><![endif]--><img width="167" height="167" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image020.jpg" /></p><p dir="RTL"><!--[if gte vml 1]><v:shape
 id="Picture_x0020_23" o:spid="_x0000_i1026" type="#_x0000_t75" style='width:124.5pt;
 height:123.75pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image021.png"
  o:title=""/>
</v:shape><![endif]--><img width="166" height="165" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image022.jpg" /></p><ul><li dir="RTL">أغلِق الزجاجة بالغطاء اللولبي البلاستيكي (لا تحتاج إلى إزالة الموائم).</li><li dir="RTL">اغسل السرنجة الفموية بالماء فقط (شكل 13).</li></ul><p dir="RTL"><!--[if gte vml 1]><v:shape
 id="Picture_x0020_25" o:spid="_x0000_i1025" type="#_x0000_t75" style='width:124.5pt;
 height:124.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image023.png"
  o:title=""/>
</v:shape><![endif]--><img width="166" height="166" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image024.jpg" /></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا تناولت كمية أكثر مما يجب من دواء ڨيمبات </strong></p><p dir="RTL">إذا تناولت كمية أكثر مما يجب من دواء ڨيمبات، يجب عليك الاتصال بطبيبك فورًا. لا تحاول ممارسة القيادة.</p><p dir="RTL">قد تتعرَّض لما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالإعياء (الغثيان)، أو إعياء (القيء).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات (نوبات تشنُّجية)، مشاكل بضربات القلب مثل: ضربات القلب البطيئة أو السريعة أو غير المنتظمة ، غيبوبة أو هبوط في ضغط الدَّم مع تسارع ضربات القلب وتعرُّق.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا أغفلت تناوُل دواء ڨيمبات</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا أغفلت تناوُل جرعة خلال الست ساعات الأولى من موعد الجرعة المقرر، فقم بتناولها بمجرد أن تتذكر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا أغفلت تناوُل جرعة بعد الست ساعات الأولى من موعد الجرعة المقرر فلا تتناول جرعة الشراب التي أغفلتها بعد ذلك. وبدلًا من ذلك تناول دواء ڨيمبات في المرة التَّالية التي يحين فيها عادة موعد تناوله.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول جرعة مضاعفة لتعويض جرعة أغفلتها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول دواء ڨيمبات</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتوقف عن تناول دواء ڨيمبات بدون التَّحدُّث إلى طبيبك؛ نظرًا لأنَّ الصَّرع الذي تعاني منه قد يعود مرة أخرى أو يتفاقم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا قرر طبيبك التَّوقف عن علاجك بدواء ڨيمبات، فسيخبرك بكيفية خفض الجرعة خطوة بخطوة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة أخرى عن استعمال هذا الدواء، فاستشر طبيبك أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>.الآثار</strong><strong> </strong><strong>الجانبية</strong><strong> </strong><strong>المحتملة</strong></p><p dir="RTL">مثل جميع الأدوية، يمكن أن يتسبب هذا الدواء في حدوث آثار جانبية على الرغم من عدم حدوث تلك الآثار الجانبية لكل من يتناوله.</p><p dir="RTL">قد تزيد الآثار الجانبية المتعلقة بالجهاز العصبي مثل الدوخة بعد تناول جرعة &quot;التحميل&quot; المفردة.</p><p dir="RTL"><strong>تحدَّث إلى طبيبك أو الصيدلي الخاص بك إذا تعرضت لأي مما يلي:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>شائعة</strong><strong> </strong><strong>جدًا</strong>: قد تؤثر &nbsp;في أكثر من 1 من كل 10 أشخاص</p><ul><li dir="RTL">الصداع</li></ul><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>شعور بدوخة أو إعياء (غثيان).</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>ازدواج الرؤية (شفع).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>شائعة</strong>: قد تؤثر &nbsp;في ما يصل إلى 1 من كل 10 أشخاص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في حفظ التوازن،وارتجاف &nbsp;)رعاش(، &nbsp;و نخز (شعور غير عادي بالتنميل &nbsp;او الحكة) أو تقلصات عضلية، والسقوط بسهولة والإصابة بكدمات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل بالذاكرة، التفكير أو إيجاد الكلمات وارتباك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حركة العينين السريعة والتي لا يمكن السيطرة عليها (رَأْرَأَة)، عدم وضوح الرؤية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالدوران (دوار)، شعور بالثمالة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إعياء (قيء) ، وجفافُ الفَم، وإمساك ، وعسر الهضم، &nbsp;وفرط الغازات في المعدة أو الأمعاء، وإسهال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف الشعور أو الإحساس، صعوبة في نطق الكلمات، اضطراب في الانتباه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضجيج في الأذن مثل: الطنين، أو الرنين، أو الصفير.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هياج، صعوبات النوم، اكتئاب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نعاس، تعب أو ضعف (وهن).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة، طفح جلدي.</p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>غير</strong><strong> </strong><strong>شائعة</strong>: قد تؤثر &nbsp;في ما يصل إلى 1 من كل 100 شخص</p><ul><li dir="RTL">بطء<strong> </strong>معدل ضربات القلب، خَفَقان، عدم انتظام النبض أو غير ذلك من التغيرات في النشاط الكهربي للقلب (اضطراب بالتَّوصيل).</li><li dir="RTL">شعور مبالغ فيه بالصحة والعافية، رؤية و/ أو سماع أشياء غير موجودة.</li><li dir="RTL">تفاعل حساسية لتناول الدواء، شرى.</li><li dir="RTL">قد تُظهِر اختبارات الدَّم اضطرابات في وظائف الكبد، الإصابات الكبدية.</li><li dir="RTL">أفكار لإيذاء نفسك أو قتلها أو محاولة الانتحار. أخبر طبيبك على الفور.</li><li dir="RTL">شعور بالغضب أو الهياج.</li><li dir="RTL">التفكير بشكل غير طبيعي أو فقدان الاتصال مع الواقع</li><li dir="RTL">تفاعل حساسية حاد يُسبب تورمًا في الوجه أو الحلق أو اليد أو القدم أو الكاحلين أو أسفل الساقين.</li><li dir="RTL">الإغماء.</li><li dir="RTL">&nbsp;صعوبات في تناسق حركاتك أو المشي.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>غير</strong><strong> </strong><strong>معروفة</strong>: لا يمكن تقدير معدل التكرار من البيانات المُتاحة</p><ul><li dir="RTL">ضربات قلب سريعة غير طبيعية (اضْطِّراب النَّظْمِ التَّسَرُّعِيّ البطيني).</li><li dir="RTL">التهاب الحَلْق، ارتفاع درجة الحرارة والإصابة بالعدوى بصورة أكثر من المُعتاد. قد تظهر اختبارات الدَّم انخفاضًا حادًا في فئة معينة من خلايا الدم البيضاء )ندرة خلايا المحببات).</li><li dir="RTL">رد فعل جلدي حاد والذي قد يتضمن ارتفاع درجة الحرارة وأعراضًا أخرى مشابهة لأعراض الإنفلونزا ، طفح جلدى على الوجه، طفح جلدى منتشر ، تورُّم الغدد (تضخم العقد الليمفاوية). &nbsp;قد تُظهِر اختبارات الدَّم ارتفاع مستويات إنزيمات الكبد ، و أحد أنواع خلايا الدم البيضاء (كثرة خلايا اليُوزينِيَّات).</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح منتشر مقرونًا ببثرات وتقشير الجلد، وخاصة حول الفم والأنف والعين والأعضاء التناسلية (متلازمة ستيفن جونسون)، وشكل أكثر حدة من الطفح يتسبب في تقشير الجلد في ما يزيد عن 30% من سطح الجسم (انحلال البشرة السام).</p><ul><li dir="RTL">تشنجات.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الإضافية في الأطفال </strong></p><p dir="RTL"><strong>شائعة: </strong>قد تُؤثر في ما يصل إلى 1 من كل 10&nbsp;أطفال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيلان الأنف (التهاب البلعوم الأنفي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حُمى (ارتفاع درجة الحرارة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الحلق (التهاب البلعوم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول الطعام بشكل أقل من المعتاد.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>غير شائعة</strong>: قد تُؤثر في ما يصل إلى 1 من كل 100&nbsp;طفل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالنُّعاس أو النَّقص في الطاقة(خمول).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروفة</strong>: لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيُّرات في السلوك، عدم التَّصرف على طبيعتهم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا أصبت بأي من الآثار الجانبية، فيُرجى إبلاغ الطبيب أو الصيدلي. ويشمل هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. من خلال الإبلاغ عن الآثار الجانبية، يُمكنك المساعدة في تقديم المزيد من المعلومات حول أمان هذا الدَّواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>5.كيفية</strong><strong> </strong><strong>تخزين</strong><strong> </strong><strong>دواء</strong><strong> </strong><strong>ڨيمبات</strong></p><p dir="RTL">يحفظ هذا الدواء بعيدًا عن رؤية ومتناول الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية الموضح على علبة الكرتون والزجاجة بعد الصيغة المختصرة EXP، يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر الموضح.</p><p dir="RTL">لا تخزن الدواء في درجة حرارة أعلى من30 درجة مئوية.</p><p dir="RTL">ولا يتم وضعه في الثلاجة.</p><p dir="RTL">. بمجرد فتح زجاجة الشراب، لا تستخدمها <u>بعد مرور شهرين</u>.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف أو المخلفات المنزلية. اسأل الصيدلي الخاص بك عن كيفية التخلص من الأدوية التي لم تعد تُستخدم. إذ تساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>6. محتويات العبوة ومعلومات أخرى </strong></p><p dir="RTL"><strong>ما الذي يحتوي عليه ڨيمبات؟</strong></p><p dir="RTL">المادة الفعالة هي لاكوساميد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي لاكوساميد. يحتوي كل 1 ملل من شراب ڨيمبات على 10 ملغم لاكوساميد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; المكوِّنات الأخرى هي جليسرول (E422)، كرميلوز الصوديوم، سوربيتول سائل ) متبلور ( (E420)، بولي إيثيلين جلايكول 4000، كلوريد الصوديوم، حمض السيتريك اللا مائي ، أسيسولفام البوتاسيوم (E950)، ميثيل بارا هيدروكسي بنزوات الصوديوم (E219)، نكهة الفراولة (تحتوي على بروبيلين جليكول، مالتول)، نكهة حاجبة (تحتوي على بروبيلين جليكول، أسبارتام (E951)، أسيسولفام البوتاسيوم (E950)، ماء مالتول منزوع الأيونات) ، ماء مُقطر.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ما شكل دواء ڨيمبات؟ وما محتويات العبوة؟</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء ڨيمبات 10 ملغم/ ملل شراب هو سائل صاف لزج قليلًا، عديم اللون ويميل إلى الأصفر الغامق -البني.</p><p dir="RTL">يتوفردواء ڨيمبات في زجاجة بها 200 ملل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي العبوات الكرتونية لدواء ڨيمبات شراب على كوب قياس بحجم 30 ملل به علامات تدرُّج وسرنجة فموية بحجم 10 ملل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; كوب القياس مناسب للبالغين و المراهقين والأطفال الذين يزنون 50 كجم فأكثر. تعادل كل علامة تدريج على كوب القياس (5 ملل) 50 ملغم من لاكوساميد (على سبيل المثال: تُعادل علامتي تدرج 100 ملغم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; السرنجة الفموية مناسبة للأطفال والمراهقين الذين تقل أوزانهم عن 50 كجم. السرنجة الفموية الممتلئة الواحدة بمقدار 10 ملل تُعادِل 100 ملغم من لاكوساميد. الحد الأدنى للكمية المُستَخلَصة هو 1 ملل، والذي يُعادل 10 ملغم من لاكوساميد. بعد ذلك، كل علامة تدريج (0.25 ملل) تُعادِل 2.5 ملغم من لاكوساميد (على سبيل المثال: الأربع علامات على التَّدريج تُعادِل 10 ملغم).</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك</strong><strong> </strong><strong>حق</strong><strong> </strong><strong>التفويض</strong><strong> </strong><strong>بالتسويق</strong></p><p dir="RTL">UCB Pharma S.A.,</p><p dir="RTL">All&eacute;e de la Recherche 60,</p><p dir="RTL">B- 1070 Bruxelles, Belgium</p><p dir="RTL"><strong>Batch releaser</strong></p><p dir="RTL">Aesica Pharmaceuticals GmbH,</p><p dir="RTL">Alfred Nobel Strasse 10, 40789 Monheim Am Rhein, Germany</p><p dir="RTL"><strong>جهة</strong><strong> </strong><strong>التصنيع</strong></p><p dir="RTL">Unither Manufacturing, LLC</p><p dir="RTL">331 Clay Road (755 Jefferson Road)</p><p dir="RTL">Rochester, NY 14623, USA</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            آخر مراجعة لهذه النشرة تمت في {09/201706/2019}
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1.	NAME OF THE MEDICINAL PRODUCT

Vimpat 10 mg/ml syrup


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2.	QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml of syrup contains 10 mg lacosamide.
1 bottle of 200 ml contains 2,000 mg lacosamide.

Excipients with known effect:
Each ml of Vimpat syrup contains 187 mg sorbitol (E420), 2.60 mg sodium methyl parahydroxybenzoate (E219), 0.032 mg aspartame (E951), and 1.42 mg sodium. 

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3.	PHARMACEUTICAL FORM

Syrup.
A slightly viscous clear, colourless to yellow-brown liquid.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic indications</strong></p><p><u>&nbsp;</u></p><p>Vimpat is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4&nbsp;years of age with epilepsy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.2&nbsp;&nbsp;&nbsp;&nbsp; Posology and method of administration</strong></p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>Lacosamide must be taken twice a day (usually once in the morning and once in the evening).</p><p>Lacosamide may be taken with or without food.</p><p>If a dose is missed, the patient should be instructed to take the missed dose immediately, and then to take the next dose of lacosamide at the regularly scheduled time. If the patient notices the missed dose within 6&nbsp;hours of the next one, he/she should be instructed to wait to take the next dose of lacosamide at the regularly scheduled time. Patients should not take a double dose.</p><p>&nbsp;</p><p><em><u>Adolescents </u></em><em><u>a</u></em><em><u>nd children </u></em><em><u>weighing 50</u></em>&nbsp;<em><u>kg or more, and adults</u></em></p><p>&nbsp;</p><p>The following table summarises the recommended posology for adolescents and children weighing 50&nbsp;kg or more, and for adults. More details are provided in the table below.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:619px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Monotherapy</p></td><td style="vertical-align:top"><p>Adjunctive therapy</p></td></tr><tr><td style="vertical-align:top"><p>Starting dose</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>100&nbsp;mg/day or 200&nbsp;mg/day</p></td><td style="vertical-align:top"><p>100&nbsp;mg/day</p></td></tr><tr><td style="vertical-align:top"><p>Single loading dose</p><p>(if applicable)</p></td><td style="vertical-align:top"><p>200&nbsp;mg</p></td><td style="vertical-align:top"><p>200&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>Titration (incremental steps)</p></td><td style="vertical-align:top"><p>50&nbsp;mg twice a day (100&nbsp;mg/day) at weekly intervals</p></td><td style="vertical-align:top"><p>50&nbsp;mg twice a day (100&nbsp;mg/day) at weekly intervals</p></td></tr><tr><td style="vertical-align:top"><p>Maximum recommended dose</p></td><td style="vertical-align:top"><p>up to 600&nbsp;mg/day</p></td><td style="vertical-align:top"><p>up to 400&nbsp;mg/day</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Monotherapy</em><em> </em></p><p>The recommended starting dose is 50&nbsp;mg twice a day which should be increased to an initial therapeutic dose of 100&nbsp;mg twice a day after one week.</p><p>Lacosamide can also be initiated at the dose of 100&nbsp;mg twice a day based on the physician&#39;s assessment of required seizure reduction versus potential side effects.</p><p>Depending on response and tolerability, the maintenance dose can be further increased at weekly intervals by 50&nbsp;mg twice a day (100&nbsp;mg/day), up to a maximum recommended daily dose of 300&nbsp;mg twice a day (600&nbsp;mg/day).</p><p>In patients having reached a dose greater than 400&nbsp;mg/day and who need an additional antiepileptic medicinal product, the posology that is recommended for adjunctive therapy below should be followed.</p><p>&nbsp;</p><p><em>Adjunctive therapy</em><em> </em></p><p>The recommended starting dose is 50&nbsp;mg twice a day which should be increased to an initial therapeutic dose of 100&nbsp;mg twice a day after one week.</p><p>Depending on response and tolerability, the maintenance dose can be further increased at weekly intervals by 50&nbsp;mg twice a day (100&nbsp;mg/day), up to a maximum recommended daily dose of 400&nbsp;mg (200&nbsp;mg twice a day).</p><p>&nbsp;</p><p><em>Initiation of lacosamide treatment with a loading dose </em></p><p>Lacosamide treatment may also be initiated with a single loading dose of 200&nbsp;mg, followed approximately 12&nbsp;hours later by a 100&nbsp;mg twice a day (200&nbsp;mg/day) maintenance dose regimen. Subsequent dose adjustments should be performed according to individual response and tolerability as described above. A loading dose may be initiated in patients in situations when the physician determines that rapid attainment of lacosamide steady state plasma concentration and therapeutic effect is warranted. It should be administered under medical supervision with consideration of the potential for increased incidence of serious cardiac arrhythmia and central nervous system adverse reactions (see section 4.8). Administration of a loading dose has not been studied in acute conditions such as status epilepticus.</p><p>&nbsp;</p><p><em>Discontinuation</em></p><p>In accordance with current clinical practice, if lacosamide has to be discontinued, it is recommended this be done gradually (e.g. taper the daily dose by 200&nbsp;mg/week).</p><p>In patients who develop serious cardiac arrhythmia, clinical benefit/risk assessment should be performed and if needed lacosamide should be discontinued.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Elderly (over 65&nbsp;years of age)</em></p><p>No dose reduction is necessary in elderly patients. Age associated decreased renal clearance with an increase in AUC levels<strong> </strong>should be considered in elderly patients (see following paragraph &lsquo;renal impairment&rsquo; and section 5.2). There is limited clinical data in the elderly patients with epilepsy, particularly at doses greater than 400&nbsp;mg/day (see sections 4.4, 4.8, and 5.1).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dose adjustment is necessary in mildly and moderately renally impaired adult and paediatric patients (CL<sub>CR</sub> &gt;&nbsp;30&nbsp;ml/min). In paediatric patients weighing 50&nbsp;kg or more and in adult patients with mild or moderate renal impairment a loading dose of 200&nbsp;mg may be considered, but further dose titration (&gt;&nbsp;200&nbsp;mg daily) should be performed with caution. In paediatric patients weighing 50&nbsp;kg or more and in adult patients with severe renal impairment (CL<sub>CR</sub> &le;&nbsp;30&nbsp;ml/min) or with end-stage renal disease, a maximum dose of 250&nbsp;mg/day is recommended and the dose titration should be performed with caution. If a loading dose is indicated, an initial dose of 100&nbsp;mg followed by a 50&nbsp;mg twice daily regimen for the first week should be used. In paediatric patients weighing less than 50&nbsp;kg with severe renal impairment (CL<sub>CR</sub> &le;&nbsp;30&nbsp;ml/min) and in those with end-stage renal disease, a reduction of 25&nbsp;% of the maximum dose is recommended. For all patients requiring haemodialysis a supplement of up to 50&nbsp;% of the divided daily dose directly after the end of haemodialysis is recommended. Treatment of patients with end-stage renal disease should be made with caution as there is little clinical experience and accumulation of a metabolite (with no known pharmacological activity).</p><p><u>&nbsp;</u></p><p><em>Hepatic impairment</em></p><p>A maximum dose of 300&nbsp;mg/day is recommended for paediatric patients weighing 50&nbsp;kg or more and for adult patients with mild to moderate hepatic impairment.</p><p>The dose titration in these patients should be performed with caution considering co-existing renal impairment. In adolescents and adults weighing 50&nbsp;kg or more, a loading dose of 200&nbsp;mg may be considered, but further dose titration (&gt;&nbsp;200&nbsp;mg daily) should be performed with caution. Based on data in adults, in paediatric patients weighing less than 50&nbsp;kg with mild to moderate hepatic impairment a reduction of 25&nbsp;% of the maximum dose should be applied. The pharmacokinetics of lacosamide has not been evaluated in severely hepatic impaired patients (see section 5.2). Lacosamide should be administered to adult and paediatric patients with severe hepatic impairment only when the expected therapeutic benefits are anticipated to outweigh the possible risks. The dose may need to be adjusted while carefully observing disease activity and potential side effects in the patient.</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p><em>&nbsp;</em></p><p>The physician should prescribe the most appropriate formulation and strength according to weight and dose.</p><p>&nbsp;</p><p><em><u>Adolescents and children weighing 50&nbsp;kg or more</u></em></p><p>Dosage in adolescents and children weighing 50&nbsp;kg or more is the same as in adults (see above).</p><p>&nbsp;</p><p><em><u>C</u></em><em><u>hildren (from 4&nbsp;years of age) and adolescents weighing less than 50&nbsp;kg</u></em></p><p>The dose is determined based on body weight. It is therefore recommended to initiate treatment with the syrup and switch to tablets, if desired. When prescribing the syrup the dose should be expressed in volume (ml) rather than weight (mg).</p><p><em>&nbsp;</em></p><p><em>Monotherapy </em></p><p>The recommended starting dose is 2&nbsp;mg/kg/day which should be increased to an initial therapeutic dose of 4&nbsp;mg/kg/day after one week.</p><p>Depending on response and tolerability, the maintenance dose can be further increased by 2&nbsp;mg/kg/day every week. The dose should be gradually increased until the optimum response is obtained. In children weighing less than 40&nbsp;kg, a maximum dose of up to 12&nbsp;mg/kg/day is recommended. In children weighing from 40 to under 50&nbsp;kg, a maximum dose of 10&nbsp;mg/kg/day is recommended.</p><p>&nbsp;</p><p>The following table summarises the recommended posology in monotherapy for children and adolescents weighing less than 50&nbsp;kg.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Starting dose</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>2&nbsp;mg/kg/day</p></td></tr><tr><td style="vertical-align:top"><p>Single loading dose</p></td><td style="vertical-align:top"><p>Not recommended</p></td></tr><tr><td style="vertical-align:top"><p>Titration (incremental steps)</p></td><td style="vertical-align:top"><p>2&nbsp;mg/kg/day every week</p></td></tr><tr><td style="vertical-align:top"><p>Maximum recommended dose in patients &lt;&nbsp;40&nbsp;kg</p></td><td style="vertical-align:top"><p>up to 12&nbsp;mg/kg/day</p></td></tr><tr><td style="vertical-align:top"><p>Maximum recommended dose in patients &ge;&nbsp;40&nbsp;kg to &lt;&nbsp;50&nbsp;kg</p></td><td style="vertical-align:top"><p>up to 10&nbsp;mg/kg/day</p></td></tr></tbody></table><p>&nbsp;</p><p>The tables below provide examples of volumes of syrup per intake depending on prescribed dose and body weight. The precise volume of syrup is to be calculated according to the exact body weight of the child.</p><p>&nbsp;</p><p>Monotherapy doses <strong>to be taken twice daily</strong> for children from 4&nbsp;years of age <strong>weighing less than 40&nbsp;kg</strong><sup>(1)</sup>:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Weight</p></td><td style="vertical-align:top"><p>0.1 ml/kg</p><p>(1 mg/kg)</p><p>Starting dose</p></td><td style="vertical-align:top"><p>0.2 ml/kg</p><p>(2 mg/kg)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.3 ml/kg</p><p>(3 mg/kg)</p></td><td style="vertical-align:top"><p>0.4 ml/kg</p><p>(4 mg/kg)</p></td><td style="vertical-align:top"><p>0.5 ml/kg</p><p>(5 mg/kg)</p></td><td style="vertical-align:top"><p>0.6 ml/kg</p><p>(6 mg/kg)</p><p>Maximum recommended dose</p></td></tr><tr><td style="vertical-align:top"><p>10 kg</p></td><td style="vertical-align:top"><p>1 ml</p><p>(10 mg)</p></td><td style="vertical-align:top"><p>2 ml</p><p>(20 mg)</p></td><td style="vertical-align:top"><p>3 ml</p><p>(30 mg)</p></td><td style="vertical-align:top"><p>4 ml</p><p>(40 mg)</p></td><td style="vertical-align:top"><p>5 ml</p><p>(50 mg)</p></td><td style="vertical-align:top"><p>6 ml</p><p>(60 mg)</p></td></tr><tr><td style="vertical-align:top"><p>15 kg</p></td><td style="vertical-align:top"><p>1.5 ml</p><p>(15 mg)</p></td><td style="vertical-align:top"><p>3 ml</p><p>(30 mg)</p></td><td style="vertical-align:top"><p>4.5 ml</p><p>(45 mg)</p></td><td style="vertical-align:top"><p>6 ml</p><p>(60 mg)</p></td><td style="vertical-align:top"><p>7.5 ml</p><p>(75 mg)</p></td><td style="vertical-align:top"><p>9 ml</p><p>(90 mg)</p></td></tr><tr><td style="vertical-align:top"><p>20 kg</p></td><td style="vertical-align:top"><p>2 ml</p><p>(20 mg)</p></td><td style="vertical-align:top"><p>4 ml</p><p>(40 mg)</p></td><td style="vertical-align:top"><p>6 ml</p><p>(60 mg)</p></td><td style="vertical-align:top"><p>8 ml</p><p>(80 mg)</p></td><td style="vertical-align:top"><p>10 ml</p><p>(100 mg)</p></td><td style="vertical-align:top"><p>12 ml</p><p>(120 mg)</p></td></tr><tr><td style="vertical-align:top"><p>25 kg</p></td><td style="vertical-align:top"><p>2.5 ml</p><p>(25 mg)</p></td><td style="vertical-align:top"><p>5 ml</p><p>(50 mg)</p></td><td style="vertical-align:top"><p>7.5 ml</p><p>(75 mg)</p></td><td style="vertical-align:top"><p>10 ml</p><p>(100 mg)</p></td><td style="vertical-align:top"><p>12.5 ml</p><p>(125 mg)</p></td><td style="vertical-align:top"><p>15 ml</p><p>(150 mg)</p></td></tr><tr><td style="vertical-align:top"><p>30 kg</p></td><td style="vertical-align:top"><p>3 ml</p><p>(30 mg)</p></td><td style="vertical-align:top"><p>6 ml</p><p>(60 mg)</p></td><td style="vertical-align:top"><p>9 ml</p><p>(90 mg)</p></td><td style="vertical-align:top"><p>12 ml</p><p>(120 mg)</p></td><td style="vertical-align:top"><p>15 ml</p><p>(150 mg)</p></td><td style="vertical-align:top"><p>18 ml</p><p>(180 mg)</p></td></tr><tr><td style="vertical-align:top"><p>35 kg</p></td><td style="vertical-align:top"><p>3.5 ml</p><p>(35 mg)</p></td><td style="vertical-align:top"><p>7 ml</p><p>(70 mg)</p></td><td style="vertical-align:top"><p>10.5 ml</p><p>(105 mg)</p></td><td style="vertical-align:top"><p>14 ml</p><p>(140 mg)</p></td><td style="vertical-align:top"><p>17.5 ml</p><p>(175 mg)</p></td><td style="vertical-align:top"><p>21 ml</p><p>(210 mg)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><sup>(1)</sup><sup> </sup>children and adolescents less than 50&nbsp;kg should preferably start the treatment with Vimpat 10&nbsp;mg/ml syrup.</p></td></tr></tbody></table><p>&nbsp;</p><p>Monotherapy doses <strong>to be taken twice daily</strong> for children and adolescents from 4&nbsp;years of age <strong>weighing 40</strong>&nbsp;<strong>kg to under 50&nbsp;kg</strong><sup>(1) (2)</sup>:</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Weight</p></td><td style="vertical-align:top"><p>0.1 ml/kg</p><p>(1 mg/kg)</p><p>Starting dose</p></td><td style="vertical-align:top"><p>0.2 ml/kg</p><p>(2 mg/kg)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.3 ml/kg</p><p>(3 mg/kg)</p></td><td style="vertical-align:top"><p>0.4 ml/kg</p><p>(4 mg/kg)</p></td><td style="vertical-align:top"><p>0.5 ml/kg</p><p>(5 mg/kg)</p><p>Maximum recommended dose</p></td></tr><tr><td style="vertical-align:top"><p>40 kg</p></td><td style="vertical-align:top"><p>4 ml</p><p>(40 mg)</p></td><td style="vertical-align:top"><p>8 ml</p><p>(80 mg)</p></td><td style="vertical-align:top"><p>12 ml</p><p>(120 mg)</p></td><td style="vertical-align:top"><p>16 ml</p><p>(160 mg)</p></td><td style="vertical-align:top"><p>20 ml</p><p>(200 mg)</p></td></tr><tr><td style="vertical-align:top"><p>45 kg</p></td><td style="vertical-align:top"><p>4.5 ml</p><p>(45 mg)</p></td><td style="vertical-align:top"><p>9 ml</p><p>(90 mg)</p></td><td style="vertical-align:top"><p>13.5 ml</p><p>(135 mg)</p></td><td style="vertical-align:top"><p>18 ml</p><p>(180 mg)</p></td><td style="vertical-align:top"><p>22.5 ml</p><p>(225 mg)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><sup>(1) </sup>children and adolescents less than 50&nbsp;kg should preferably start the treatment with Vimpat 10&nbsp;mg/ml syrup</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><sup>(2) </sup>Dosage in adolescents 50&nbsp;kg or more is the same as in adults.</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p><em>Adjunctive therapy </em></p><p>The recommended starting dose is 2&nbsp;mg/kg/day which should be increased to an initial therapeutic dose of 4&nbsp;mg/kg/day after one week.</p><p>Depending on response and tolerability, the maintenance dose can be further increased by 2&nbsp;mg/kg/day every week. The dose should be gradually adjusted until the optimum response is obtained. In children weighing less than 20&nbsp;kg, due to an increased clearance compared to adults, a maximum dose of up to 12&nbsp;mg/kg/day is recommended. In children weighing from 20 to under 30&nbsp;kg, a maximum dose of 10&nbsp;mg/kg/day is recommended and in children weighing from 30 to under 50&nbsp;kg a maximum dose of 8&nbsp;mg/kg/day is recommended, although in open-label studies (see sections 4.8 and 5.2), a dose up to 12&nbsp;mg/kg/day has been used by a small number of these children.</p><p>&nbsp;</p><p>The following table summarises the recommended posology in adjunctive therapy for children and adolescents weighing less than 50 kg.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Starting dose</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>2&nbsp;mg/kg/day</p></td></tr><tr><td style="vertical-align:top"><p>Single loading dose</p></td><td style="vertical-align:top"><p>Not recommended</p></td></tr><tr><td style="vertical-align:top"><p>Titration (incremental steps)</p></td><td style="vertical-align:top"><p>2&nbsp;mg/kg/day every week</p></td></tr><tr><td style="vertical-align:top"><p>Maximum recommended dose in patients to &lt;&nbsp;20&nbsp;kg</p></td><td style="vertical-align:top"><p>up to 12&nbsp;mg/kg/day</p></td></tr><tr><td style="vertical-align:top"><p>Maximum recommended dose in patients &ge;&nbsp;20&nbsp;kg to &lt;&nbsp;30&nbsp;kg</p></td><td style="vertical-align:top"><p>up to 10&nbsp;mg/kg/day</p></td></tr><tr><td style="vertical-align:top"><p>Maximum recommended dose in patients &ge;&nbsp;30&nbsp;kg to &lt;&nbsp;50&nbsp;kg</p></td><td style="vertical-align:top"><p>up to 8&nbsp;mg/kg/day</p></td></tr></tbody></table><p>&nbsp;</p><p>The tables below provide examples of volumes of syrup per intake depending on prescribed dose and body weight. The precise volume of syrup is to be calculated according to the exact body weight of the child.</p><p>&nbsp;</p><p>Adjunctive therapy doses <strong>to be taken twice daily</strong> for children from 4&nbsp;years of age <strong>weighing less than 20 kg</strong><sup>(1)</sup>:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Weight</p></td><td style="vertical-align:top"><p>0.1 ml/kg</p><p>(1 mg/kg)</p><p>Starting dose</p></td><td style="vertical-align:top"><p>0.2 ml/kg</p><p>(2 mg/kg)</p></td><td style="vertical-align:top"><p>0.3 ml/kg</p><p>(3 mg/kg)</p></td><td style="vertical-align:top"><p>0.4 ml/kg</p><p>(4 mg/kg)</p></td><td style="vertical-align:top"><p>0.5 ml/kg</p><p>(5 mg/kg)</p></td><td style="vertical-align:top"><p>0.6 ml/kg</p><p>(6 mg/kg)</p><p>Maximum recommended dose</p></td></tr><tr><td style="vertical-align:top"><p>10 kg</p></td><td style="vertical-align:top"><p>1 ml</p><p>(10 mg)</p></td><td style="vertical-align:top"><p>2 ml</p><p>(20 mg)</p></td><td style="vertical-align:top"><p>3 ml</p><p>(30 mg)</p></td><td style="vertical-align:top"><p>4 ml</p><p>(40 mg)</p></td><td style="vertical-align:top"><p>5 ml</p><p>(50 mg)</p></td><td style="vertical-align:top"><p>6 ml</p><p>(60 mg)</p></td></tr><tr><td style="vertical-align:top"><p>15 kg</p></td><td style="vertical-align:top"><p>1.5 ml</p><p>(15 mg)</p></td><td style="vertical-align:top"><p>3 ml</p><p>(30 mg)</p></td><td style="vertical-align:top"><p>4.5 ml</p><p>(45 mg)</p></td><td style="vertical-align:top"><p>6 ml</p><p>(60 mg)</p></td><td style="vertical-align:top"><p>7.5 ml</p><p>(75 mg)</p></td><td style="vertical-align:top"><p>9 ml</p><p>(90 mg)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><sup>(1) </sup>children and adolescents less than 50 kg should preferably start the treatment with Vimpat 10&nbsp;mg/ml syrup</p></td></tr></tbody></table><p>&nbsp;</p><p>Adjunctive therapy doses <strong>to be taken twice daily</strong> for children and adolescents from 4&nbsp;years of age <strong>weighing 20&nbsp;kg to under 30&nbsp;kg</strong><sup>(1)</sup>:</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Weight</p></td><td style="vertical-align:top"><p>0.1 ml/kg</p><p>(1 mg/kg)</p><p>Starting dose</p></td><td style="vertical-align:top"><p>0.2 ml/kg</p><p>(2 mg/kg)</p></td><td style="vertical-align:top"><p>0.3 ml/kg</p><p>(3 mg/kg)</p></td><td colspan="2" style="vertical-align:top"><p>0.4 ml/kg</p><p>(4 mg/kg)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.5 ml/kg</p><p>(5 mg/kg)</p><p>Maximum recommended dose</p></td></tr><tr><td style="vertical-align:top"><p>20 kg</p></td><td style="vertical-align:top"><p>2 ml</p><p>(20 mg)</p></td><td style="vertical-align:top"><p>4 ml</p><p>(40 mg)</p></td><td style="vertical-align:top"><p>6 ml</p><p>(60 mg)</p></td><td colspan="2" style="vertical-align:top"><p>8 ml</p><p>(80 mg)</p></td><td style="vertical-align:top"><p>10 ml</p><p>(100 mg)</p></td></tr><tr><td style="vertical-align:top"><p>25 kg</p></td><td style="vertical-align:top"><p>2.5 ml</p><p>(25 mg)</p></td><td style="vertical-align:top"><p>5 ml</p><p>(50 mg)</p></td><td style="vertical-align:top"><p>7.5 ml</p><p>(75 mg)</p></td><td colspan="2" style="vertical-align:top"><p>10 ml</p><p>(100 mg)</p></td><td style="vertical-align:top"><p>12.5 ml</p><p>(125 mg)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>(1) </sup>children and adolescents less than 50 kg should preferably start the treatment with Vimpat 10&nbsp;mg/ml syrup</p></td><td colspan="2" style="vertical-align:top"><p><sup>&nbsp;</sup></p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>Adjunctive therapy doses <strong>to be taken twice </strong><strong>daily</strong> for children and adolescents from 4&nbsp;years of age <strong>weighing 30&nbsp;kg to under 50&nbsp;kg</strong><sup>(1)</sup>:</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Weight</p></td><td style="vertical-align:top"><p>0.1 ml/kg</p><p>(1 mg/kg)</p><p>Starting dose</p></td><td style="vertical-align:top"><p>0.2 ml/kg</p><p>(2 mg/kg)</p></td><td style="vertical-align:top"><p>0.3 ml/kg</p><p>(3 mg/kg)</p></td><td style="vertical-align:top"><p>0.4 ml/kg</p><p>(4 mg/kg)</p><p>Maximum recommended dose</p></td></tr><tr><td style="vertical-align:top"><p>30 kg</p></td><td style="vertical-align:top"><p>3 ml (30 mg)</p></td><td style="vertical-align:top"><p>6 ml (60 mg)</p></td><td style="vertical-align:top"><p>9 ml (90 mg)</p></td><td style="vertical-align:top"><p>12 ml (120 mg)</p></td></tr><tr><td style="vertical-align:top"><p>35 kg</p></td><td style="vertical-align:top"><p>3.5 ml (35 mg)</p></td><td style="vertical-align:top"><p>7 ml (70 mg)</p></td><td style="vertical-align:top"><p>10.5 ml (105 mg)</p></td><td style="vertical-align:top"><p>14 ml (140 mg)</p></td></tr><tr><td style="vertical-align:top"><p>40 kg</p></td><td style="vertical-align:top"><p>4 ml (40 mg)</p></td><td style="vertical-align:top"><p>8 ml (80 mg)</p></td><td style="vertical-align:top"><p>12 ml (120 mg)</p></td><td style="vertical-align:top"><p>16 ml (160 mg)</p></td></tr><tr><td style="vertical-align:top"><p>45 kg</p></td><td style="vertical-align:top"><p>4.5 ml (45 mg)</p></td><td style="vertical-align:top"><p>9 ml (90 mg)</p></td><td style="vertical-align:top"><p>13.5 ml (135 mg)</p></td><td style="vertical-align:top"><p>18 ml (180 mg)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>(1) </sup>children and adolescents less than 50 kg should preferably start the treatment with Vimpat 10&nbsp;mg/ml syrup</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Loading dose</em></p><p>Administration of a loading dose has not been studied in children. Use of a loading dose is not recommended in adolescents and children weighing less than 50&nbsp;kg.</p><p>&nbsp;</p><p><em><u>Children less than 4 years</u></em></p><p>The safety and efficacy of lacosamide in children aged below 4&nbsp;years have not yet been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Lacosamide syrup must be taken orally.</p><p>&nbsp;</p><p>The bottle containing Vimpat syrup should be shaken well before use. Lacosamide may be taken with or without food.</p><p>Lacosamide syrup is provided with a measuring cup with graduation marks (for patients weighing 50&nbsp;kg or more) and with an oral syringe with an adaptor (for patients weighing less than 50&nbsp;kg).</p><p><u>&nbsp;</u></p><p><em>Measuring cup </em>(<em>for adolescents and children weighing 50&nbsp;kg or more, and adults</em>)</p><p>Each graduation mark (5&nbsp;ml) of the measuring cup corresponds to 50&nbsp;mg lacosamide.</p><p>&nbsp;</p><p><em>Dosing oral syringe (10&nbsp;ml graduated every 0.25&nbsp;ml) with an adaptor </em>(<em>for</em> <em>children and adolescents from 4&nbsp;years of age<s> </s>weighing less than 50&nbsp;kg</em>)</p><p>One full oral syringe (10&nbsp;ml) corresponds to 100&nbsp;mg of lacosamide. The minimum extractable volume is 1&nbsp;ml which is 10&nbsp;mg of lacosamide. As from the 1&nbsp;ml graduation mark, each graduation corresponds to 0.25&nbsp;ml which is 2.5&nbsp;mg of lacosamide.</p><p>&nbsp;</p><p>Instructions for use are provided in the package leaflet.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4.3	Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Known second- or third-degree atrioventricular (AV) block. 


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.4&nbsp;&nbsp;&nbsp;&nbsp; Special warnings and precautions for use</strong></p><p>&nbsp;</p><p><u>Suicidal ideation and behaviour</u></p><p>&nbsp;</p><p>Suicidal ideation and behaviour have been reported in patients treated with antiepileptic medicinal products in several indications. A meta-analysis of randomised placebo-controlled trials of antiepileptic medicinal products has also shown a small increased risk of suicidal ideation and behaviour. The mechanism of this risk is not known and the available data do not exclude the possibility of an increased risk for lacosamide.</p><p>Therefore, patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge (see section 4.8).</p><p>&nbsp;</p><p><u>Cardiac rhythm and conduction</u></p><p>&nbsp;</p><p>Dose-related prolongations in PR interval with lacosamide have been observed in clinical studies. Lacosamide should be used with caution in patients with underlying proarrhythmic conditions such as patients with known cardiac conduction problems or severe cardiac disease (e.g. myocardial ischaemia/infarction, heart failure, structural heart disease or cardiac sodium channelopathies) or patients treated with medicinal products affecting cardiac conduction, including antiarrhythmics and sodium channel blocking antiepileptic medicinal products (see section 4.5), as well as in elderly patients.</p><p>In these patients it should be considered to perform an ECG before a lacosamide dose increase above 400&nbsp;mg/day and after lacosamide is titrated to steady-state.</p><p>&nbsp;</p><p>In the placebo-controlled trials of lacosamide in epilepsy patients, atrial fibrillation or flutter were not reported; however, both have been reported in open-label epilepsy trials and in post-marketing experience.</p><p>&nbsp;</p><p>In post-marketing experience, AV block (including second degree or higher AV block) has been reported. In patients with proarrhythmic conditions, ventricular tachyarrhythmia has been reported. In rare cases, these events have led to asystole, cardiac arrest and death in patients with underlying proarrhythmic conditions.</p><p>&nbsp;</p><p>Patients should be made aware of the symptoms of cardiac arrhythmia (e.g. slow, rapid or irregular pulse, palpitations, shortness of breath, feeling lightheaded, fainting). Patients should be counselled to seek immediate medical advice if these symptoms occur.</p><p>&nbsp;</p><p><u>Dizziness</u></p><p>&nbsp;</p><p>Treatment with lacosamide has been associated with dizziness which could increase the occurrence of accidental injury or falls. Therefore, patients should be advised to exercise caution until they are familiar with the potential effects of the medicine (see section 4.8).</p><p>&nbsp;</p><p><u>Potential for electro-clinical worsening in specific paediatric epilepsy syndromes</u></p><p>&nbsp;</p><p>The safety and efficacy of lacosamide in paediatric patients with epilepsy syndromes in which focal and generalised seizures may coexist have not been determined.</p><p>&nbsp;</p><p><u>Excipients</u></p><p>&nbsp;</p><p><em>Excipients which may cause intolerance</em></p><p>Vimpat syrup contains sodium methyl parahydroxybenzoate (E219), which may cause allergic reactions (possibly delayed).</p><p>Vimpat syrup contains sorbitol (E420). Patients with rare hereditary problems of fructose intolerance should not take this medicine.</p><p>Vimpat syrup contains aspartame (E951), a source of phenylalanine, which may be harmful for people with phenylketonuria.</p><p>&nbsp;</p><p><em>Sodium content</em></p><p>Vimpat syrup contains sodium. To be taken into consideration by patients on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.5&nbsp;&nbsp;&nbsp;&nbsp; Interaction with other medicinal products and other forms of interaction</strong></p><p><strong>&nbsp;</strong></p><p>Lacosamide should be used with caution in patients treated with medicinal products known to be associated with PR prolongation (including sodium channel blocking antiepileptic medicinal products) and in patients treated with antiarrhythmics. However, subgroup analysis in clinical trials did not identify an increased magnitude of PR prolongation in patients with concomitant administration of carbamazepine or lamotrigine.</p><p><em><u>&nbsp;</u></em></p><p><em><u>In vitro</u></em><u> data</u></p><p>&nbsp;</p><p>Data generally suggest that lacosamide has a low interaction potential. <em>In vitro</em> studies indicate that the enzymes CYP1A2, CYP2B6, and CYP2C9 are not induced and that CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2D6, and CYP2E1 are not inhibited by lacosamide at plasma concentrations observed in clinical trials. An <em>in vitro</em> study indicated that lacosamide is not transported by P‑glycoprotein in the intestine. <em>In vitro</em> data show that CYP2C9, CYP2C19 and CYP3A4 are capable of catalysing the formation of the O-desmethyl metabolite.</p><p><em>&nbsp;</em></p><p><em><u>In vivo</u></em><u> data</u></p><p>&nbsp;</p><p>Lacosamide does not inhibit or induce CYP2C19 and CYP3A4 to a clinically relevant extent. Lacosamide did not affect the AUC of midazolam (metabolised by CYP3A4, lacosamide given 200&nbsp;mg twice a day) but C<sub>max</sub> of midazolam was slightly increased (30&nbsp;%). Lacosamide did not affect the pharmacokinetics of omeprazole (metabolised by CYP2C19 and CYP3A4, lacosamide given 300&nbsp;mg twice a day).</p><p>The CYP2C19 inhibitor omeprazole (40&nbsp;mg once daily) did not give rise to a clinically significant change in lacosamide exposure. Thus, moderate inhibitors of CYP2C19 are unlikely to affect systemic lacosamide exposure to a clinically relevant extent.</p><p>Caution is recommended in concomitant treatment with strong inhibitors of CYP2C9 (e.g.</p><p>fluconazole) and CYP3A4 (e.g. itraconazole, ketoconazole, ritonavir, clarithromycin), which may lead to increased systemic exposure of lacosamide. Such interactions have not been established <em>in vivo</em> but are possible based on <em>in vitro</em> data.</p><p>&nbsp;</p><p>Strong enzyme inducers such as rifampicin or St.&nbsp;John&rsquo;s wort (Hypericum perforatum) may moderately reduce the systemic exposure of lacosamide. Therefore, starting or ending treatment with these enzyme inducers should be done with caution.</p><p>&nbsp;</p><p><u>Antiepileptic medicinal products</u></p><p>&nbsp;</p><p>In interaction trials lacosamide did not significantly affect the plasma concentrations of carbamazepine and valproic acid. Lacosamide plasma concentrations were not affected by carbamazepine and by valproic acid. Population pharmacokinetic analyses in different age groups estimated that concomitant treatment with other antiepileptic medicinal products known to be enzyme inducers (carbamazepine, phenytoin, phenobarbital, in various doses) decreased the overall systemic exposure of lacosamide by 25&nbsp;% in adults and 17&nbsp;% in paediatric patients.</p><p>&nbsp;</p><p><u>Oral contraceptives</u></p><p>&nbsp;</p><p>In an interaction trial there was no clinically relevant interaction between lacosamide and the oral contraceptives ethinylestradiol and levonorgestrel. Progesterone concentrations were not affected when the medicinal products were co-administered.</p><p>&nbsp;</p><p><u>Others</u></p><p>&nbsp;</p><p>Interaction trials showed that lacosamide had no effect on the pharmacokinetics of digoxin. There was no clinically relevant interaction between lacosamide and metformin.</p><p>Co-administration of warfarin with lacosamide does not result in a clinically relevant change in the pharmacokinetics and pharmacodynamics of warfarin.</p><p>Although no pharmacokinetic data on the interaction of lacosamide with alcohol are available, a pharmacodynamic effect cannot be excluded.</p><p>Lacosamide has a low protein binding of less than 15&nbsp;%. Therefore, clinically relevant interactions with other medicinal products through competition for protein binding sites are considered unlikely.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.6&nbsp;&nbsp;&nbsp;&nbsp; Fertility, pregnancy and lactation</strong></p><p><em>&nbsp;</em></p><p><u>Pregnancy</u></p><p>&nbsp;</p><p><em>Risk related to epilepsy and antiepileptic medicinal products in general </em></p><p>For all antiepileptic medicinal products, it has been shown that in the offspring of treated women with epilepsy, the prevalence of malformations is two to three times greater than the rate of approximately 3&nbsp;% in the general population. In the treated population, an increase in malformations has been noted with polytherapy, however, the extent to which the treatment and/or the illness is responsible has not been elucidated.</p><p>Moreover, effective antiepileptic therapy must not be interrupted, since the aggravation of the illness is detrimental to both the mother and the foetus.</p><p>&nbsp;</p><p><em>Risk related to lacosamide</em></p><p>There are no adequate data from the use of lacosamide in pregnant women. Studies in animals did not indicate any teratogenic effects in rats or rabbits, but embryotoxicity was observed in rats and rabbits at maternal toxic doses (see section 5.3). The potential risk for humans is unknown.</p><p>Lacosamide should not be used during pregnancy unless clearly necessary (if the benefit to the mother clearly outweighs the potential risk to the foetus). If women decide to become pregnant, the use of this product should be carefully re-evaluated.</p><p><u>&nbsp;</u></p><p><u>Breastfeeding</u></p><p>&nbsp;</p><p>It is unknown whether lacosamide is excreted in human breast milk. A risk to the newborns/infants cannot be excluded. Animal studies have shown excretion of lacosamide in breast milk. For precautionary measures, breast-feeding should be discontinued during treatment with lacosamide.</p><p><strong>&nbsp;</strong></p><p><u>Fertility</u></p><p>&nbsp;</p><p>No adverse reactions on male or female fertility or reproduction were observed in rats at doses producing plasma exposures (AUC) up to approximately 2 times the plasma AUC in humans at the maximum recommended human dose (MRHD).</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects on ability to drive and use machines</strong></p><p>&nbsp;</p><p>Lacosamide has minor to moderate influence on the ability to drive and use machines. Lacosamide treatment has been associated with dizziness or blurred vision.</p><p>Accordingly, patients should be advised not to drive or to operate other potentially hazardous machinery until they are familiar with the effects of lacosamide on their ability to perform such activities.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.8&nbsp;&nbsp;&nbsp; Undesirable effects</strong></p><p>&nbsp;</p><p><u>Summary of safety profile</u></p><p>&nbsp;</p><p>Based on the analysis of pooled placebo-controlled clinical trials in adjunctive therapy in 1,308&nbsp;patients with partial-onset seizures, a total of 61.9&nbsp;% of patients randomised to lacosamide and 35.2&nbsp;% of patients randomised to placebo reported at least 1&nbsp;adverse reaction. The most frequently reported adverse reactions (&ge;&nbsp;10&nbsp;%) with lacosamide treatment were dizziness, headache, nausea and diplopia. They were usually mild to moderate in intensity. Some were dose-related and could be alleviated by reducing the dose. Incidence and severity of central nervous system (CNS) and gastrointestinal (GI) adverse reactions usually decreased over time.</p><p>In all of these controlled studies, the discontinuation rate due to adverse reactions was 12.2&nbsp;% for patients randomised to lacosamide and 1.6&nbsp;% for patients randomised to placebo. The most common adverse reaction resulting in discontinuation of lacosamide therapy was dizziness.</p><p>Incidence of CNS adverse reactions such as dizziness may be higher after a loading dose.</p><p>&nbsp;</p><p>Based on the analysis of data from a non-inferiority monotherapy clinical trial comparing lacosamide to carbamazepine controlled release (CR), the most frequently reported adverse reactions (&ge;&nbsp;10&nbsp;%) for lacosamide were headache and dizziness. The discontinuation rate due to adverse reactions was 10.6&nbsp;% for patients treated with lacosamide and 15.6&nbsp;% for patients treated with carbamazepine CR.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>The table below shows the frequencies of adverse reactions which have been reported in clinical trials and post-marketing experience. The frequencies are defined as follows: very common (&ge;&nbsp;1/10), common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10), uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100) and not known (frequency cannot be estimated from available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:98%"><thead><tr><td style="vertical-align:top"><p>System organ class</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Not known</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Blood and lymphatic disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Agranulocytosis<sup>(1)</sup></p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Drug hypersensitivity<sup>(1)</sup></p></td><td style="vertical-align:top"><p>Drug reaction with eosinophilia and systemic symptoms (DRESS)<sup> (1,2)</sup></p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Depression</p><p>Confusional state</p><p>Insomnia<sup>(1)</sup></p></td><td style="vertical-align:top"><p>Aggression</p><p>Agitation<sup>(1)</sup></p><p>Euphoric mood<sup>(1)</sup></p><p>Psychotic disorder<sup>(1)</sup></p><p>Suicide attempt<sup> (1)</sup></p><p>Suicidal ideation</p><p>Hallucination<sup> (1)</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Dizziness</p><p>Headache</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Balance disorder</p><p>Memory impairment</p><p>Cognitive disorder</p><p>Somnolence</p><p>Tremor</p><p>Nystagmus</p><p>Hypoesthesia</p><p>Dysarthria</p><p>Disturbance in attention</p><p>Paraesthesia</p></td><td style="vertical-align:top"><p>Syncope<sup>(2)</sup></p><p>Coordination abnormal</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Convulsion<sup>(3)</sup></p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Diplopia</p></td><td style="vertical-align:top"><p>Vision blurred</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vertigo</p><p>Tinnitus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Atrioventricular block<sup>(1,2)</sup></p><p>Bradycardia<sup>(1,2)</sup></p><p>Atrial Fibrillation <sup>(1,2)</sup></p><p>Atrial Flutter <sup>(1,2)</sup></p></td><td style="vertical-align:top"><p>Ventricular tachyarrhythmia <sup>(1)</sup></p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Nausea</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vomiting</p><p>Constipation</p><p>Flatulence</p><p>Dyspepsia</p><p>Dry mouth</p><p>Diarrhoea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Liver function test abnormal<sup>(2)</sup></p><p>Hepatic enzyme increased (&gt;&nbsp;2x&nbsp;ULN)<sup> (1)</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pruritus</p><p>Rash<sup>(1)</sup></p></td><td style="vertical-align:top"><p>Angioedema<sup>(1)</sup></p><p>Urticaria<sup>(1)</sup></p></td><td style="vertical-align:top"><p>Stevens-Johnson syndrome<sup>(1)</sup></p><p>Toxic epidermal necrolysis<sup>(1)</sup></p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Muscle spasms</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Gait disturbance</p><p>Asthenia</p><p>Fatigue</p><p>Irritability</p><p>Feeling drunk</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Fall</p><p>Skin laceration</p><p>Contusion</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><sup>(1) </sup>Adverse reactions reported in post marketing experience.</p><p><sup>(2) </sup>See Description of selected adverse reactions.</p><p><sup>(3)</sup> Reported in open-label studies.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p>The use of lacosamide is associated with dose-related increase in the PR interval. Adverse reactions associated with PR interval prolongation (e.g. atrioventricular block, syncope, bradycardia) may occur.</p><p>In adjunctive clinical trials in epilepsy patients, the incidence rate of reported first-degree AV Block is uncommon, 0.7&nbsp;%, 0&nbsp;%, 0.5&nbsp;% and 0&nbsp;%<strong> </strong>for lacosamide 200&nbsp;mg, 400&nbsp;mg, 600&nbsp;mg or placebo, respectively. No second- or higher degree AV Block was seen in these studies. However, cases with second- and third-degree AV Block associated with lacosamide treatment have been reported in post-marketing experience. In the monotherapy clinical trial comparing lacosamide to carbamazepine CR, the extent of increase in PR interval was comparable between lacosamide and carbamazepine.</p><p>The incidence rate for syncope reported in pooled adjunctive therapy clinical trials is uncommon and did not differ between lacosamide (n=944) treated epilepsy patients (0.1&nbsp;%) and placebo (n=364) treated epilepsy patients (0.3&nbsp;%). In the monotherapy clinical trial comparing lacosamide to carbamazepine CR, syncope was reported in 7/444 (1.6&nbsp;%) lacosamide patients and in 1/442 (0.2&nbsp;%) carbamazepine CR patients.</p><p>Atrial fibrillation or flutter were not reported in short term clinical trials; however, both have been reported in open-label epilepsy trials and in post-marketing experience.</p><p>&nbsp;</p><p><em>Laboratory abnormalities</em></p><p>Abnormalities in liver function tests have been observed in placebo-controlled trials with lacosamide in adult patients with partial-onset seizures who were taking 1 to 3 concomitant antiepileptic medicinal products. Elevations of ALT to &ge;&nbsp;3x&nbsp;ULN occurred in 0.7&nbsp;% (7/935) of Vimpat patients and 0&nbsp;% (0/356) of placebo patients.</p><p><u>&nbsp;</u></p><p><em>Multiorgan hypersensitivity reactions</em></p><p>Multiorgan hypersensitivity reactions (also known as Drug Reaction with Eosinophilia and Systemic Symptoms, DRESS) have been reported in patients treated with some antiepileptic medicinal products. These reactions are variable in expression but typically present with fever and rash and can be associated with involvement of different organ systems. If multiorgan hypersensitivity reaction is suspected, lacosamide should be discontinued.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The safety profile of lacosamide in placebo-controlled (see study details in section 5.1) and in open-label studies (n=408) in adjunctive therapy in children from 4&nbsp;years of age was consistent with the safety profile observed in adults although the frequency of some adverse reactions (somnolence, vomiting and convulsion) was increased and additional adverse reactions (nasopharyngitis, pyrexia, pharyngitis, decreased appetite, lethargy and abnormal behaviour) have been reported in paediatric patients: nasopharyngitis (15.7&nbsp;%), vomiting (14.7&nbsp;%), somnolence (14.0&nbsp;%), dizziness (13.5&nbsp;%), pyrexia (13.0&nbsp;%), convulsion (7.8&nbsp;%), decreased appetite (5.9&nbsp;%), pharyngitis (4.7 %), lethargy (2.7&nbsp;%) and abnormal behaviour (1.7&nbsp;%).</p><p>A total of 67.8 % of patients randomised to lacosamide and 58.1 % of patients randomised to placebo reported at least 1 adverse reaction.</p><p>Behavioural, cognition and emotional functioning were measured by the questionnaires Achenbach CBCL and BRIEF that were applied at baseline and throughout the studies and where mainly stable during the course of the trials.</p><p>&nbsp;</p><p><u>Elderly population </u></p><p>&nbsp;</p><p>In the monotherapy study comparing lacosamide to carbamazepine CR, the types of adverse reactions related to lacosamide in elderly patients (&ge;&nbsp;65&nbsp;years of age) appear to be similar to that observed in patients less than 65&nbsp;years of age. However, a higher incidence (&ge;&nbsp;5&nbsp;% difference) of fall, diarrhoea and tremor has been reported in elderly patients compared to younger adult patients. The most frequent cardiac-related adverse reaction reported in elderly compared to the younger adult population was first-degree AV block. This was reported with lacosamide in 4.8&nbsp;% (3/62) in elderly patients versus 1.6&nbsp;% (6/382) in younger adult patients. The discontinuation rate due to adverse events observed with lacosamide was 21.0&nbsp;% (13/62) in elderly patients versus 9.2&nbsp;% (35/382) in younger adult patients. These differences between elderly and younger adult patients were similar to those observed in the active comparator group.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.</p><p>&nbsp;</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>&middot;&nbsp;&nbsp; &nbsp;<strong><em>Saudi Arabia:</em></strong></p><p><!--[if gte vml 1]><v:rect
 id="Rectangle_x0020_2" o:spid="_x0000_s1027" style='position:absolute;
 margin-left:-2.25pt;margin-top:4.8pt;width:467.35pt;height:108.2pt;z-index:251659264;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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=
" filled="f"/><![endif]--><img width="625" height="147" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image001.gif" />&nbsp;</p><p>&nbsp;</p><p>-&nbsp; &nbsp;The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p><p>-&nbsp; &nbsp;Please contact the relevant competent authority.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</strong></p><p>&nbsp;</p><p><u>Symptoms</u></p><p><u>&nbsp;</u></p><p>Symptoms observed after an accidental or intentional overdose of lacosamide are primarily associated with CNS and gastrointestinal system.</p><ul><li>The types of adverse reactions experienced by patients exposed to doses above 400&nbsp;mg up to 800&nbsp;mg were not clinically different from those of patients administered recommended doses of lacosamide.</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reactions reported after an intake of more than 800&nbsp;mg are dizziness, nausea, vomiting, seizures (generalised tonic-clonic seizures, status epilepticus). Cardiac conduction disorders, shock and coma have also been observed. Fatalities have been reported in patients following an intake of acute single overdose of several grams of lacosamide.</p><p>&nbsp;</p><p><u>Management</u></p><p>&nbsp;</p><p>There is no specific antidote for overdose with lacosamide. Treatment of lacosamide overdose should include general supportive measures and may include haemodialysis if necessary (see section 5.2).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.1 &nbsp;&nbsp;&nbsp; Pharmacodynamic properties</strong></p><p>&nbsp;</p><p>Pharmacotherapeutic group: antiepileptics, other antiepileptics, ATC code: N03AX18</p><p><u>&nbsp;</u></p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>The active substance, lacosamide (R‑2‑acetamido‑N‑benzyl‑3‑methoxypropionamide) is a functionalised amino acid.</p><p>The precise mechanism by which lacosamide exerts its antiepileptic effect in humans remains to be fully elucidated. <em>In vitro</em> electrophysiological studies have shown that lacosamide selectively enhances slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes.</p><p><u>&nbsp;</u></p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p>Lacosamide protected against seizures in a broad range of animal models of partial and primary generalised seizures and delayed kindling development.</p><p>In non-clinical experiments lacosamide in combination with levetiracetam, carbamazepine, phenytoin, valproate, lamotrigine, topiramate or gabapentin showed synergistic or additive anticonvulsant effects.</p><p><u>&nbsp;</u></p><p><u>Clinical efficacy and safety</u></p><p><u>Adult populatio</u><u>n</u></p><p><em>&nbsp;</em></p><p><em>Monotherapy</em></p><p>Efficacy of lacosamide as monotherapy was established in a double-blind, parallel group, non-inferiority comparison to carbamazepine CR in 886&nbsp;patients 16&nbsp;years of age or older with newly or recently diagnosed epilepsy. The patients had to present with unprovoked partial-onset seizures with or without secondary generalisation. The patients were randomised to carbamazepine CR or lacosamide, provided as tablets, in a 1:1 ratio. The dose was based on dose-response and ranged from 400 to 1,200&nbsp;mg/day for carbamazepine CR and from 200 to 600&nbsp;mg/day for lacosamide. The duration of the treatment was up to 121&nbsp;weeks depending on the response.</p><p>The estimated 6-month seizure freedom rates were 89.8&nbsp;% for lacosamide-treated patients and 91.1&nbsp;% for carbamazepine CR treated patients using the Kaplan-Meier survival analysis method. The adjusted absolute difference between treatments was -1.3&nbsp;% (95&nbsp;% CI: -5.5, 2.8). The Kaplan-Meier estimates of 12-month seizure freedom rates were 77.8&nbsp;% for lacosamide-treated patients and 82.7&nbsp;% for carbamazepine CR treated patients.</p><p>The 6-month seizure freedom rates in elderly patients of 65 and above (62&nbsp;patients in lacosamide, 57&nbsp;patients in carbamazepine CR) were similar between both treatment groups. The rates were also similar to those observed in the overall population. In the elderly population, the maintenance lacosamide dose was 200&nbsp;mg/day in 55&nbsp;patients (88.7&nbsp;%), 400&nbsp;mg/day in 6&nbsp;patients (9.7&nbsp;%) and the dose was escalated to over 400&nbsp;mg/day in 1&nbsp;patient (1.6&nbsp;%).</p><p>&nbsp;</p><p><em>Conversion to monotherapy</em></p><p>The efficacy and safety of lacosamide in conversion to monotherapy has been assessed in a historical-controlled, multicentre, double-blind, randomised trial. In this study, 425&nbsp;patients aged 16 to 70&nbsp;years with uncontrolled partial-onset seizures taking stable doses of 1 or 2 marketed antiepileptic medicinal products were randomised to be converted to lacosamide monotherapy (either 400&nbsp;mg/day or 300&nbsp;mg/day in a 3:1 ratio). In treated patients who completed titration and started withdrawing antiepileptic medicinal products (284 and 99 respectively), monotherapy was maintained in 71.5&nbsp;% and 70.7&nbsp;% of patients respectively for 57-105&nbsp;days (median 71&nbsp;days), over the targeted observation period of 70&nbsp;days.</p><p>&nbsp;</p><p><strong>Adjunctive therapy</strong></p><p><strong>The efficacy of lacosamide as adjunctive therapy at recommended doses (200&nbsp;mg/day, 400&nbsp;mg/day) was established in 3 multicenter, </strong><strong>randomised, placebo-controlled clinical trials with a 12‑week maintenance period. Lacosamide 600&nbsp;mg/day was also shown to be effective in controlled adjunctive therapy trials, although the efficacy was similar to 400&nbsp;mg/day and patients were less likely to tolerate this dose because of CNS- and gastrointestinal-related adverse reactions. Thus, the 600&nbsp;mg/day dose is not recommended. The maximum recommended dose is 400&nbsp;mg/day. These trials, involving 1,308&nbsp;patients with a history of an average of 23&nbsp;years of partial-onset seizures, were designed to evaluate the efficacy and safety of lacosamide when administered concomitantly with 1‑3 </strong>antiepileptic medicinal products <strong>in patients with uncontrolled partial-onset seizures with or without secondary generalisation. </strong>Overall the proportion of subjects with a 50&nbsp;% reduction in seizure frequency was 23&nbsp;%, 34&nbsp;%, and 40&nbsp;% for placebo, lacosamide 200&nbsp;mg/day and lacosamide 400&nbsp;mg/day.</p><p>&nbsp;</p><p><strong>The pharmacokinetics and safety of a single loading dose of intravenous lacosamide were determined in a multicenter, open-label study designed to assess the safety and tolerability of rapid initiation of lacosamide using a single intravenous loading dose (including 200&nbsp;mg) followed by twice daily oral dosing (equivalent to the intravenous dose) as adjunctive therapy in adult subjects 16 to 60&nbsp;years of age with partial-onset seizures. </strong></p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>Partial-onset seizures have a similar clinical expression in children from 4&nbsp;years of age and in adults. The efficacy of lacosamide in children aged 4&nbsp;years and older has been extrapolated from data of adolescents and adults with partial-onset seizures, for whom a similar response was expected provided the paediatric dose adaptations are established (see section 4.2) and safety has been demonstrated (see section 4.8).</p><p>The efficacy supported by the extrapolation principle stated above was confirmed by a double-blind, randomised, placebo-controlled study. The study consisted of an 8-week baseline period followed by a 6-week titration period. Eligible patients on a stable dose regimen of 1 to &le;&nbsp;3&nbsp;antiepileptic medicinal products, who still experienced at least 2&nbsp;partial onset-seizures during the 4&nbsp;weeks prior to screening with seizure-free phase no longer than 21&nbsp;days in the 8-week period prior to entry into the baseline period, were randomised to receive either placebo (n=172) or lacosamide (n=171).</p><p>Dosing was initiated at a dose of 2&nbsp;mg/kg/day in subjects weighing less than 50&nbsp;kg or 100&nbsp;mg/day in subjects weighing 50&nbsp;kg or more in 2 divided doses. During the titration period, lacosamide doses were adjusted in 1or 2&nbsp;mg/kg/day increments in subjects weighing less than 50&nbsp;kg or 50 or 100&nbsp;mg/day in subjects weighing 50&nbsp;kg or more at weekly intervals to achieve the target maintenance period dose range.</p><p>Subjects must have achieved the minimum target dose for their body weight category for the final 3&nbsp;days of the titration period to be eligible for entry into the 10-week maintenance period. Subjects were to remain on stable lacosamide dose throughout the maintenance period or were withdrawn and entered in the blinded taper period.</p><p>Statistically significant (p=0.0003) and clinically relevant reduction in partial-onset seizure frequency per 28&nbsp;days from baseline to the maintenance period was observed between the lacosamide and the placebo group. The percent reduction over placebo based on analysis of covariance was 31.72&nbsp;% (95&nbsp;% CI: 16.342, 44.277).</p><p>Overall, the proportion of subjects with at least a 50&nbsp;% reduction in partial-onset seizure frequency per 28&nbsp;days from baseline to the maintenance period was 52.9&nbsp;% in the lacosamide group compared with 33.3&nbsp;% in the placebo group.</p><p>The quality of life assessed by the Pediatric Quality of Life Inventory indicated that subjects in both lacosamide and placebo groups had a similar and stable health-related quality of life during the entire treatment period.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic properties</strong></p><p>&nbsp;</p><p><u>Absorption </u></p><p>&nbsp;</p><p>Lacosamide is rapidly and completely absorbed after oral administration. The oral bioavailability of lacosamide tablets is approximately 100&nbsp;%. Following oral administration, the plasma concentration of unchanged lacosamide increases rapidly and reaches C<sub>max</sub> about 0.5 to 4&nbsp;hours post-dose. Vimpat tablets and syrup are bioequivalent. Food does not affect the rate and extent of absorption.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>The volume of distribution is approximately 0.6&nbsp;L/kg. Lacosamide is less than 15&nbsp;% bound to plasma proteins.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>95&nbsp;% of the dose is excreted in the urine as lacosamide and metabolites. The metabolism of lacosamide has not been completely characterised.</p><p>The major compounds excreted in urine are unchanged lacosamide (approximately 40&nbsp;% of the dose) and its O‑desmethyl metabolite less than 30&nbsp;%.</p><p>A polar fraction proposed to be serine derivatives accounted for approximately 20&nbsp;% in urine, but was detected only in small amounts (0‑2&nbsp;%) in human plasma of some subjects. Small amounts (0.5‑2&nbsp;%) of additional metabolites were found in the urine.</p><p><em>In vitro</em> data show that CYP2C9, CYP2C19 and CYP3A4 are capable of catalysing the formation of the O‑desmethyl metabolite but the main contributing isoenzyme has not been confirmed<em> in vivo</em>. No clinically relevant difference in lacosamide exposure was observed comparing its pharmacokinetics in extensive metabolisers (EMs, with a functional CYP2C19) and poor metabolisers (PMs, lacking a functional CYP2C19). Furthermore an interaction trial with omeprazole (CYP2C19‑inhibitor) demonstrated no clinically relevant changes in lacosamide plasma concentrations indicating that the importance of this pathway is minor. The plasma concentration of O‑desmethyl‑lacosamide is approximately 15&nbsp;% of the concentration of lacosamide in plasma. This major metabolite has no known pharmacological activity.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>Lacosamide is primarily eliminated from the systemic circulation by renal excretion and biotransformation. After oral and intravenous administration of radiolabeled lacosamide, approximately 95&nbsp;% of radioactivity administered was recovered in the urine and less than 0.5&nbsp;% in the faeces. The elimination half-life of lacosamide is approximately 13&nbsp;hours. The pharmacokinetics is dose-proportional and constant over time, with low intra- and inter-subject variability. Following twice daily dosing, steady state plasma concentrations are achieved after a 3&nbsp;day period. The plasma concentration increases with an accumulation factor of approximately 2.</p><p>&nbsp;</p><p>A single loading dose of 200&nbsp;mg approximates steady-state concentrations comparable to 100&nbsp;mg twice daily oral administration.</p><p>&nbsp;</p><p><u>Pharmacokinetics in special patient groups</u></p><p><u>&nbsp;</u></p><p><em>Gender</em></p><p>Clinical trials indicate that gender does not have a clinically significant influence on the plasma concentrations of lacosamide.</p><p><u>&nbsp;</u></p><p><em>Renal impairment</em></p><p>The AUC of lacosamide was increased by approximately 30&nbsp;% in mildly and moderately and 60&nbsp;% in severely renal impaired patients and patients with end-stage renal disease requiring haemodialysis compared to healthy subjects, whereas C<sub>max</sub> was unaffected.</p><p>Lacosamide is effectively removed from plasma by haemodialysis. Following a 4‑hour haemodialysis treatment, AUC of lacosamide is reduced by approximately 50&nbsp;%. Therefore, dosage supplementation following haemodialysis is recommended (see section 4.2). The exposure of the O‑desmethyl metabolite was several-fold increased in patients with moderate and severe renal impairment. In absence of haemodialysis in patients with end-stage renal disease, the levels were increased and continuously rising during the 24‑hour sampling. It is unknown whether the increased metabolite exposure in end-stage renal disease subjects could give rise to adverse effects but no pharmacological activity of the metabolite has been identified.</p><p><u>&nbsp;</u></p><p><em>Hepatic impairment</em></p><p>Subjects with moderate hepatic impairment (Child-Pugh B) showed higher plasma concentrations of lacosamide (approximately 50&nbsp;% higher AUC<sub>norm</sub>). The higher exposure was partly due to a reduced renal function in the studied subjects. The decrease in non-renal clearance in the patients of the study was estimated to give a 20&nbsp;% increase in the AUC of lacosamide. The pharmacokinetics of lacosamide has not been evaluated in severe hepatic impairment (see section 4.2).</p><p><u>&nbsp;</u></p><p><em>Elderly (over 65 years of age)</em></p><p>In a study in elderly men and women including 4 patients &gt;&nbsp;75 years of age, AUC was about 30 and 50&nbsp;% increased compared to young men, respectively. This is partly related to lower body weight. The body weight normalized difference is 26 and 23&nbsp;%, respectively. An increased variability in exposure was also observed. The renal clearance of lacosamide was only slightly reduced in elderly subjects in this study.</p><p>A general dose reduction is not considered to be necessary unless indicated due to reduced renal function (see section 4.2).</p><p><strong>&nbsp;</strong></p><p><em>Paediatric population</em></p><p>The paediatric pharmacokinetic profile of lacosamide was determined in a population pharmacokinetic analysis using sparse plasma concentration data obtained in one placebo-controlled randomised study and three open-label studies in 414&nbsp;children with epilepsy aged 6&nbsp;months to 17&nbsp;years. The administered lacosamide doses ranged from 2 to 17.8&nbsp;mg/kg/day in twice daily intake, with a maximum of 600&nbsp;mg/day for children weighing 50&nbsp;kg or more.</p><p>The typical plasma clearance was estimated to be 1.04&nbsp;L/h, 1.32&nbsp;L/h and 1.86&nbsp;L/h for children weighing 20&nbsp;kg, 30&nbsp;kg and 50&nbsp;kg respectively. In comparison, plasma clearance was estimated at 1.92&nbsp;L/h in adults (70&nbsp;kg body weight).</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.3&nbsp;&nbsp;&nbsp;&nbsp; Preclinical safety data</strong></p><p>&nbsp;</p><p>In the toxicity studies, the plasma concentrations of lacosamide obtained were similar or only marginally higher than those observed in patients, which leaves low or non-existing margins to human exposure.</p><p>A safety pharmacology study with intravenous administration of lacosamide in anesthetised dogs showed transient increases in PR interval and QRS complex duration and decreases in blood pressure most likely due to a cardiodepressant action. These transient changes started in the same concentration range as after maximum recommended clinical dosing. In anesthetised dogs and Cynomolgus monkeys, at intravenous doses of 15-60&nbsp;mg/kg, slowing of atrial and ventricular conductivity, atrioventricular block and atrioventricular dissociation were seen.</p><p>In the repeated dose toxicity studies, mild reversible liver changes were observed in rats starting at about 3 times the clinical exposure. These changes included an increased organ weight, hypertrophy of hepatocytes, increases in serum concentrations of liver enzymes and increases in total cholesterol and triglycerides. Apart from the hypertrophy of hepatocytes, no other histopathologic changes were observed.</p><p>In reproductive and developmental toxicity studies in rodents and rabbits, no teratogenic effects but an increase in numbers of stillborn pups and pup deaths in the peripartum period, and slightly reduced live litter sizes and pup body weights were observed at maternal toxic doses in rats corresponding to systemic exposure levels similar to the expected clinical exposure. Since higher exposure levels could not be tested in animals due to maternal toxicity, data are insufficient to fully characterise the embryofetotoxic and teratogenic potential of lacosamide.</p><p>Studies in rats revealed that lacosamide and/or its metabolites readily crossed the placental barrier.</p><p>In juvenile rats and dogs, the types of toxicity do not differ qualitatively from those observed in adult animals. In juvenile rats, a reduced body weight was observed at systemic exposure levels similar to the expected clinical exposure. In juvenile dogs, transient and dose-related CNS clinical signs started to be observed at systemic exposure levels below the expected clinical exposure.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.1&nbsp;&nbsp;&nbsp;&nbsp; List of excipients</strong></p><p>&nbsp;</p><p>Glycerol (E422)</p><p>Carmellose sodium</p><p>Sorbitol liquid (crystallizing) (E420)</p><p>Polyethylene glycol 4000</p><p>Sodium chloride</p><p>Citric acid, anhydrous</p><p>Acesulfame potassium (E950)</p><p>Sodium methyl parahydroxybenzoate (E219)</p><p>Strawberry flavour (contains propylene glycol, maltol)</p><p>Masking flavour (contains propylene glycol, aspartame (E951), acesulfame potassium (E950), maltol, deionised water)</p><p>purified water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.2&nbsp;&nbsp;&nbsp;&nbsp; Incompatibilities</strong></p><p>&nbsp;</p><p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                6.3	Shelf life

3 years
After first opening: 2 months

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.4&nbsp;&nbsp;&nbsp;&nbsp; Special precautions for storage</strong></p><p>&nbsp;</p><p>Do not store above 30&deg;C</p><p>&nbsp;</p><p>Do not refrigerate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.5&nbsp;&nbsp;&nbsp;&nbsp; Nature and contents of container</strong></p><p>&nbsp;</p><p>A 200&nbsp;ml amber glass bottle with white polypropylene screw cap, a measuring cup and an oral syringe with an adaptor.</p><p>Each graduation mark (5&nbsp;ml) of the 30&nbsp;ml measuring cup corresponds to 50&nbsp;mg of lacosamide (for example 2 graduation marks correspond to 100&nbsp;mg).</p><p>One full 10&nbsp;ml oral syringe corresponds to 100&nbsp;mg of lacosamide. The minimum extractable volume is 1&nbsp;ml which is 10&nbsp;mg of lacosamide. As from the 1&nbsp;ml graduation mark, each graduation corresponds to 0.25&nbsp;ml which is 2.5&nbsp;mg of lacosamide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.6&nbsp;&nbsp;&nbsp;&nbsp; Special precautions for disposal</strong></p><p>&nbsp;</p><p>No special requirements for disposal.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                UCB Pharma S.A.
Allée de la Recherche 60
B 1070 Bruxelles
Belgium


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Date of first authorisation: 29 August 2008
Date of latest renewal: 31 July 2013

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>